




(12) **DEMANDE DE BREVET CANADIEN  
CANADIAN PATENT APPLICATION**

(13) **A1**

(86) Date de dépôt PCT/PCT Filing Date: 2020/12/22  
(87) Date publication PCT/PCT Publication Date: 2021/07/01  
(85) Entrée phase nationale/National Entry: 2022/06/23  
(86) N° demande PCT/PCT Application No.: US 2020/066508  
(87) N° publication PCT/PCT Publication No.: 2021/133751  
(30) Priorité/Priority: 2019/12/23 (IN201911053553)

(51) Cl.Int./Int.Cl. *C07D 403/04* (2006.01)  
(71) Demandeur/Applicant:  
BRISTOL-MYERS SQUIBB COMPANY, US  
(72) Inventeurs/Inventors:  
VELAPARTHI, UPENDER, US;  
OLSON, RICHARD E., US;  
WARRIER, JAYAKUMAR SANKARA, IN;  
RAHAMAN, HASIBUR, IN  
(74) Agent: GOWLING WLG (CANADA) LLP

(54) Titre : COMPOSES QUINAZOLINYLE SUBSTITUES UTILES EN TANT QU'ACTIVATEURS DE LYMPHOCYTES T  
(54) Title: SUBSTITUTED QUINAZOLINYL COMPOUNDS USEFUL AS T CELL ACTIVATORS



(57) **Abrégé/Abstract:**

Disclosed are compounds of Formula (I): (I) or a salt thereof, wherein: R<sub>1</sub>, R<sub>2</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub>, and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGK $\alpha$ ) and diacylglycerol kinase zeta (DGK $\zeta$ ), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.

**Date Submitted:** 2022/06/23

**CA App. No.:** 3162985

**Abstract:**

Disclosed are compounds of Formula (I): (I) or a salt thereof, wherein: R1, R2, R4, R5, R6, and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGK ) and diacylglycerol kinase zeta (DGK), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.

## SUBSTITUTED QUINAZOLINYL COMPOUNDS USEFUL AS T CELL ACTIVATORS

### CROSS REFERENCE

5           This application claims the benefit of Indian Provisional Application No.  
201911053553 filed December 23, 2019 which is incorporated herein in its entirety.

### DESCRIPTION

10           The present invention generally relates to substituted quinazolinyl compounds that  
activate T cells, promote T cell proliferation, and/or exhibit antitumor activity. Provided  
herein are substituted quinazolinyl compounds, compositions comprising such  
compounds, and methods of their use. The invention further pertains to pharmaceutical  
compositions comprising at least one compound according to the invention that are useful  
for the treatment of proliferative disorders, such as cancer, and viral infections.

15

### BACKGROUND OF THE INVENTION

Human cancers harbor numerous genetic and epigenetic alterations, generating  
neoantigens potentially recognizable by the immune system (Sjoblom et al. (2006)  
*Science* 314:268-74). The adaptive immune system, comprised of T and B lymphocytes,  
20 has powerful anti-cancer potential, with a broad capacity and exquisite specificity to  
respond to diverse tumor antigens. Further, the immune system demonstrates  
considerable plasticity and a memory component. The successful harnessing of all these  
attributes of the adaptive immune system would make immunotherapy unique among all  
cancer treatment modalities. However, although an endogenous immune response to  
25 cancer is observed in preclinical models and patients, this response is ineffective, and  
established cancers are viewed as "self" and tolerated by the immune system.  
Contributing to this state of tolerance, tumors may exploit several distinct mechanisms to  
actively subvert anti-tumor immunity. These mechanisms include dysfunctional T-cell  
signaling (Mizoguchi et al., (1992) *Science* 258:1795-98), suppressive regulatory cells  
30 (Facciabene et al., (2012) *Cancer Res.* 72:2162-71), and the co-opting of endogenous  
"immune checkpoints", which serve to down-modulate the intensity of adaptive immune  
responses and protect normal tissues from collateral damage, by tumors to evade immune

destruction (Topalian et al., (2012) *Curr. Opin. Immunol.* 24:1-6; Mellman et al. (2011) *Nature* 480:480-489).

Diacylglycerol kinases (DGKs) are lipid kinases that mediate the conversion of diacylglycerol to phosphatidic acid thereby terminating T cell functions propagated through the TCR signaling pathway. Thus, DGKs serve as intracellular checkpoints and inhibition of DGKs are expected to enhance T cell signaling pathways and T cell activation. Supporting evidence include knock-out mouse models of either DGK $\alpha$  or DGK $\zeta$  which show a hyper-responsive T cell phenotype and improved anti-tumor immune activity (Riese M.J. et al., *Journal of Biological Chemistry*, (2011) 7: 5254-5265; Zha Y et al., *Nature Immunology*, (2006) 12:1343; Olenchock B.A. et al., (2006) 11: 1174-81). Furthermore tumor infiltrating lymphocytes isolated from human renal cell carcinoma patients were observed to overexpress DGK $\alpha$  which resulted in inhibited T cell function (Prinz, P.U. et al., *J Immunology* (2012) 12:5990-6000). Thus, DGK $\alpha$  and DGK $\zeta$  are viewed as targets for cancer immunotherapy (Riese M.J. et al., *Front Cell Dev Biol.* (2016) 4: 108; Chen, S.S. et al., *Front Cell Dev Biol.* (2016) 4: 130; Avila-Flores, A. et al., *Immunology and Cell Biology* (2017) 95: 549-563; Noessner, E., *Front Cell Dev Biol.* (2017) 5: 16; Krishna, S., et al., *Front Immunology* (2013) 4:178; Jing, W. et al., *Cancer Research* (2017) 77: 5676-5686.


There remains a need for compounds useful as inhibitors of one or both of DGK $\alpha$  and DGK $\zeta$ . Additionally, there remains a need for compounds useful as inhibitors of one or both of DGK $\alpha$  and DGK $\zeta$  that have selectivity over other diacylglycerol kinases, protein kinases, and/or other lipid kinases.

Accordingly, an agent that is safe and effective in restoring T cell activation, lowering antigen threshold, enhancing antitumor functionality, and/or overcoming the suppressive effects of one or more endogenous immune checkpoints, such as PD-1, LAG-3 and TGF $\beta$ , would be an important addition for the treatment of patients with proliferative disorders, such as cancer, as well as viral infections.

#### SUMMARY OF THE INVENTION

Applicants have found compounds that have activity as inhibitors of one or both of DGK $\alpha$  and DGK $\zeta$ . Further, applicants have found compounds that have activity as





or a salt thereof, wherein:

- $R_1$  is H, F, Cl, Br,  $-\text{CN}$ ,  $\text{C}_{1-3}$  alkyl substituted with zero to 4  $R_{1a}$ ,  $\text{C}_{3-4}$  cycloalkyl substituted with zero to 4  $R_{1a}$ ,  $\text{C}_{1-3}$  alkoxy substituted with zero to 4  $R_{1a}$ ,
- 5  $-\text{C}(\text{O})\text{NR}_a\text{R}_a$ ,  $-\text{NR}_a\text{R}_a$ ,  $-\text{S}(\text{O})_n\text{R}_e$ , or  $-\text{P}(\text{O})\text{R}_e\text{R}_e$ ;
- each  $R_{1a}$  is independently F, Cl,  $-\text{CN}$ ,  $-\text{OH}$ ,  $-\text{OCH}_3$ , or  $-\text{NR}_a\text{R}_a$ ;
- each  $R_a$  is independently H or  $\text{C}_{1-3}$  alkyl;
- each  $R_e$  is independently  $\text{C}_{3-4}$  cycloalkyl or  $\text{C}_{1-3}$  alkyl substituted with zero to 4  $R_{1a}$ ;
- $R_2$  is H,  $\text{C}_{1-3}$  alkyl substituted with zero to 4  $R_{2a}$ ,  $\text{C}_{2-3}$  alkenyl substituted with zero to 4
- 10  $R_{2a}$ , or  $\text{C}_{3-4}$  cycloalkyl substituted with zero to 4  $R_{2a}$ ;
- each  $R_{2a}$  is independently F, Cl,  $-\text{CN}$ ,  $-\text{OH}$ ,  $-\text{O}(\text{C}_{1-2}$  alkyl),  $\text{C}_{3-4}$  cycloalkyl,  $\text{C}_{3-4}$  alkenyl, or  $\text{C}_{3-4}$  alkynyl;
- $R_4$  is  $-\text{CH}_2\text{R}_{4a}$ ,  $-\text{CH}_2\text{CH}_2\text{R}_{4a}$ ,  $-\text{CH}_2\text{CHR}_{4a}\text{R}_{4d}$ ,  $-\text{CHR}_{4a}\text{R}_{4b}$ , or  $-\text{CR}_{4a}\text{R}_{4b}\text{R}_{4c}$ ;
- $R_{4a}$  and  $R_{4b}$  are independently:
- 15 (i)  $\text{C}_{1-6}$  alkyl substituted with zero to 4 substituents independently selected from F, Cl,  $-\text{CN}$ ,  $-\text{OH}$ ,  $-\text{OCH}_3$ ,  $-\text{SCH}_3$ ,  $\text{C}_{1-3}$  fluoroalkoxy,  $-\text{NR}_a\text{R}_a$ ,  $-\text{S}(\text{O})_2\text{R}_e$ , or  $-\text{NR}_a\text{S}(\text{O})_2\text{R}_e$ ;
- (ii)  $\text{C}_{3-6}$  cycloalkyl, heterocyclyl, phenyl, or heteroaryl, each substituted with zero to 4 substituents independently selected from F, Cl, Br,  $-\text{CN}$ ,  $-\text{OH}$ ,  $\text{C}_{1-6}$  alkyl,  $\text{C}_{1-3}$
- 20 fluoroalkyl,  $\text{C}_{1-4}$  hydroxyalkyl,  $-(\text{CH}_2)_{1-2}\text{O}(\text{C}_{1-3}$  alkyl),  $\text{C}_{1-4}$  alkoxy,  $-\text{O}(\text{C}_{1-4}$  hydroxyalkyl),  $-\text{O}(\text{CH})_{1-3}\text{O}(\text{C}_{1-3}$  alkyl),  $\text{C}_{1-3}$  fluoroalkoxy,  $-\text{O}(\text{CH})_{1-3}\text{NR}_c\text{R}_c$ ,  $-\text{OCH}_2\text{CH}=\text{CH}_2$ ,  $-\text{OCH}_2\text{C}\equiv\text{CH}$ ,  $-\text{C}(\text{O})(\text{C}_{1-4}$  alkyl),  $-\text{C}(\text{O})\text{OH}$ ,  $-\text{C}(\text{O})\text{O}(\text{C}_{1-4}$  alkyl),  $-\text{NR}_c\text{R}_c$ ,  $-\text{NR}_a\text{S}(\text{O})_2(\text{C}_{1-3}$  alkyl),  $-\text{NR}_a\text{C}(\text{O})(\text{C}_{1-3}$  alkyl),  $-\text{NR}_a\text{C}(\text{O})\text{O}(\text{C}_{1-4}$  alkyl),  $-\text{P}(\text{O})(\text{C}_{1-3}$  alkyl) $_2$ ,  $-\text{S}(\text{O})_2(\text{C}_{1-3}$  alkyl),  $-\text{O}(\text{CH}_2)_{1-2}(\text{C}_{3-6}$  cycloalkyl),
- 25  $-\text{O}(\text{CH}_2)_{1-2}(\text{morpholinyl})$ , cyclopropyl, cyanocyclopropyl, methylazetidynyl,

acetylazetidiny, (*tert*-butoxycarbonyl)azetidiny, triazolyl, tetrahydropyranyl, morpholinyl, thiophenyl, methylpiperidinyl, and R<sub>d</sub>; or

(iii) C<sub>1-4</sub> alkyl substituted with one cyclic group selected from C<sub>3-6</sub> cycloalkyl, heterocyclyl, aryl, and heteroaryl, said cyclic group substituted with zero to 3 substituents independently selected from F, Cl, Br, -OH, -CN, C<sub>1-6</sub> alkyl, C<sub>1-3</sub> fluoroalkyl, C<sub>1-3</sub> alkoxy, C<sub>1-3</sub> fluoroalkoxy, OCH<sub>2</sub>CH-CH<sub>2</sub>, OCH<sub>2</sub>C≡CH, -NR<sub>c</sub>R<sub>c</sub>, -NR<sub>a</sub>S(O)<sub>2</sub>(C<sub>1-3</sub> alkyl), -NR<sub>a</sub>C(O)(C<sub>1-3</sub> alkyl), -NR<sub>a</sub>C(O)O(C<sub>1-4</sub> alkyl), and C<sub>3-6</sub> cycloalkyl;

or R<sub>4a</sub> and R<sub>4b</sub> together with the carbon atom to which they are attached form a C<sub>3-6</sub> cycloalkyl or a 3- to 6-membered heterocyclyl, each substituted with zero to 3 R<sub>f</sub>, each R<sub>f</sub> is independently F, Cl, Br, -OH, -CN, C<sub>1-6</sub> alkyl, C<sub>1-3</sub> fluoroalkyl, C<sub>1-3</sub> alkoxy, C<sub>1-3</sub> fluoroalkoxy, -OCH<sub>2</sub>CH=CH<sub>2</sub>, -OCH<sub>2</sub>C≡CH, -NR<sub>c</sub>R<sub>c</sub>, or a cyclic group selected from C<sub>3-6</sub> cycloalkyl, 3- to 6-membered heterocyclyl, phenyl, monocyclic heteroaryl, and bicyclic heteroaryl, each cyclic group substituted with zero to 3 substituents independently selected from F, Cl, Br, -OH, -CN, C<sub>1-6</sub> alkyl, C<sub>1-3</sub> fluoroalkyl, C<sub>1-3</sub> alkoxy, C<sub>1-3</sub> fluoroalkoxy, and -NR<sub>c</sub>R<sub>c</sub>;

R<sub>4c</sub> is C<sub>1-6</sub> alkyl or C<sub>3-6</sub> cycloalkyl, each substituted with zero to 4 substituents independently selected from F, Cl, -OH, C<sub>1-2</sub> alkoxy, C<sub>1-2</sub> fluoroalkoxy, and -CN;

R<sub>4d</sub> is -OCH<sub>3</sub>;

each R<sub>c</sub> is independently H or C<sub>1-2</sub> alkyl;

R<sub>d</sub> is phenyl substituted with zero to 1 substituent selected from F, Cl, -CN, -CH<sub>3</sub>, and -OCH<sub>3</sub>;

each R<sub>5</sub> is independently F, Cl, -CN, -OH, C<sub>1-6</sub> alkyl substituted with zero to 4 R<sub>g</sub>, C<sub>1-3</sub> alkoxy substituted with zero to 4 R<sub>g</sub>, C<sub>2-4</sub> alkenyl substituted with zero to 4 R<sub>g</sub>, C<sub>2-4</sub> alkynyl substituted with zero to 4 R<sub>g</sub>, C<sub>3-4</sub> cycloalkyl substituted with zero to 4 R<sub>g</sub>, phenyl substituted with zero to 4 R<sub>g</sub>, oxadiazolyl substituted with zero to 3 R<sub>g</sub>, pyridinyl substituted with zero to 4 R<sub>g</sub>, -(CH<sub>2</sub>)<sub>1-2</sub>(heterocyclyl substituted with zero to 4 R<sub>g</sub>), -(CH<sub>2</sub>)<sub>1-2</sub>NR<sub>c</sub>C(O)(C<sub>1-4</sub> alkyl), -(CH<sub>2</sub>)<sub>1-2</sub>NR<sub>c</sub>C(O)O(C<sub>1-4</sub> alkyl), -(CH<sub>2</sub>)<sub>1-2</sub>NR<sub>c</sub>S(O)<sub>2</sub>(C<sub>1-4</sub> alkyl), -C(O)(C<sub>1-4</sub> alkyl), -C(O)OH, -C(O)O(C<sub>1-4</sub> alkyl), -C(O)O(C<sub>3-4</sub> cycloalkyl), -C(O)NR<sub>a</sub>R<sub>a</sub>, or -C(O)NR<sub>a</sub>(C<sub>3-4</sub> cycloalkyl), or two R<sub>5</sub>

attached to the same carbon atom form =O;  
 each R<sub>g</sub> is independently F, Cl, -CN, -OH, C<sub>1-3</sub> alkoxy, C<sub>1-3</sub> fluoroalkoxy,  
 -O(CH<sub>2</sub>)<sub>1-2</sub>O(C<sub>1-2</sub> alkyl), C<sub>3-5</sub> cycloalkyl, or -NR<sub>c</sub>R<sub>c</sub>;

each R<sub>6</sub> is H, F, Cl, -CN, -CH<sub>3</sub>, -CH<sub>2</sub>F, -CHF<sub>2</sub>, -CF<sub>3</sub>, or -OCH<sub>3</sub>;

5 m is zero, 1, 2, or 3; and

n is zero, 1, or 2.

In one embodiment, a compound of Formula (I) or a salt thereof is provided  
 wherein: R<sub>1</sub> is H, F, Cl, Br, -CN, C<sub>1-3</sub> alkyl substituted with zero to 4 R<sub>1a</sub>, cyclopropyl  
 substituted with zero to 3 R<sub>1a</sub>, C<sub>1-3</sub> alkoxy substituted with zero to 3 R<sub>1a</sub>, -C(O)NR<sub>a</sub>R<sub>a</sub>,  
 10 -NR<sub>a</sub>R<sub>a</sub>, -S(O)<sub>n</sub>CH<sub>3</sub>, or -P(O)(CH<sub>3</sub>)<sub>2</sub>; each R<sub>1a</sub> is independently F, Cl, or -CN; each R<sub>a</sub> is  
 independently H or C<sub>1-3</sub> alkyl; R<sub>2</sub> is H, C<sub>1-2</sub> alkyl substituted with zero to 2 R<sub>2a</sub>, or C<sub>2-3</sub>  
 alkenyl substituted with zero to 2 R<sub>2a</sub>; each R<sub>2a</sub> is independently F, Cl, -CN, -OH,  
 -O(C<sub>1-2</sub> alkyl), cyclopropyl, C<sub>3-4</sub> alkenyl, or C<sub>3-4</sub> alkynyl; R<sub>4a</sub> and R<sub>4b</sub> are independently:  
 (i) C<sub>1-4</sub> alkyl substituted with zero to 4 substituents independently selected from F, Cl,  
 15 -CN, -OH, -OCH<sub>3</sub>, -SCH<sub>3</sub>, C<sub>1-3</sub> fluoroalkoxy, and -NR<sub>a</sub>R<sub>a</sub>; (ii) C<sub>3-6</sub> cycloalkyl,  
 heterocyclyl, phenyl, or heteroaryl, each substituted with zero to 4 substituents  
 independently selected from F, Cl, Br, -CN, -OH, C<sub>1-6</sub> alkyl, C<sub>1-3</sub> fluoroalkyl, -CH<sub>2</sub>OH,  
 -(CH<sub>2</sub>)<sub>1-2</sub>O(C<sub>1-2</sub> alkyl), C<sub>1-4</sub> alkoxy, -O(C<sub>1-4</sub> hydroxyalkyl), -O(CH)<sub>1-2</sub>O(C<sub>1-2</sub> alkyl),  
 C<sub>1-3</sub> fluoroalkoxy, -O(CH)<sub>1-2</sub>NR<sub>c</sub>R<sub>c</sub>, -OCH<sub>2</sub>CH=CH<sub>2</sub>, -OCH<sub>2</sub>C≡CH, -C(O)(C<sub>1-4</sub> alkyl),  
 20 -C(O)OH, -C(O)O(C<sub>1-4</sub> alkyl), -NR<sub>c</sub>R<sub>c</sub>, -NR<sub>a</sub>S(O)<sub>2</sub>(C<sub>1-3</sub> alkyl), -NR<sub>a</sub>C(O)(C<sub>1-3</sub> alkyl),  
 -NR<sub>a</sub>C(O)O(C<sub>1-4</sub> alkyl), -P(O)(C<sub>1-2</sub> alkyl)<sub>2</sub>, -S(O)<sub>2</sub>(C<sub>1-3</sub> alkyl), -O(CH<sub>2</sub>)<sub>1-2</sub>(C<sub>3-4</sub>  
 cycloalkyl), -O(CH<sub>2</sub>)<sub>1-2</sub>(morpholinyl), cyclopropyl, cyanocyclopropyl, methylazetidiny,  
 acetylazetidiny, (*tert*-butoxycarbonyl)azetidiny, triazolyl, tetrahydropyranyl,  
 morpholinyl, thiophenyl, methylpiperidiny, and R<sub>d</sub>; or (iii) C<sub>1-3</sub> alkyl substituted with  
 25 one cyclic group selected from C<sub>3-6</sub> cycloalkyl, heterocyclyl, phenyl, and heteroaryl, said  
 cyclic group substituted with zero to 3 substituents independently selected from F, Cl, Br,  
 -OH, -CN, C<sub>1-3</sub> alkyl, C<sub>1-2</sub> fluoroalkyl, C<sub>1-3</sub> alkoxy, C<sub>1-2</sub> fluoroalkoxy, -OCH<sub>2</sub>CH=CH<sub>2</sub>,  
 -OCH<sub>2</sub>C≡CH, -NR<sub>c</sub>R<sub>c</sub>, -NR<sub>a</sub>S(O)<sub>2</sub>(C<sub>1-3</sub> alkyl), -NR<sub>a</sub>C(O)(C<sub>1-3</sub> alkyl), -NR<sub>a</sub>C(O)O(C<sub>1-4</sub>  
 30 alkyl), and C<sub>3-4</sub> cycloalkyl; or R<sub>4a</sub> and R<sub>4b</sub> together with the carbon atom to which they  
 are attached, form a C<sub>3-6</sub> cycloalkyl or a 3- to 6-membered heterocyclyl, each substituted

with zero to 3  $R_f$ ; each  $R_f$  is independently F, Cl, Br,  $-OH$ ,  $-CN$ ,  $C_{1-4}$  alkyl,  $C_{1-2}$  fluoroalkyl,  $C_{1-3}$  alkoxy,  $C_{1-2}$  fluoroalkoxy,  $-OCH_2CH=CH_2$ ,  $-OCH_2C\equiv CH$ ,  $-NR_cR_c$ , or a cyclic group selected from  $C_{3-6}$  cycloalkyl, 3- to 6-membered heterocyclyl, phenyl, monocyclic heteroaryl, and bicyclic heteroaryl, each cyclic group substituted with zero to 3 substituents independently selected from F, Cl, Br,  $-OH$ ,  $-CN$ ,  $C_{1-4}$  alkyl,  $C_{1-2}$  fluoroalkyl,  $C_{1-3}$  alkoxy,  $C_{1-2}$  fluoroalkoxy, and  $-NR_cR_c$ ;  $R_{4c}$  is  $C_{1-4}$  alkyl or  $C_{3-6}$  cycloalkyl, each substituted with zero to 4 substituents independently selected from F, Cl,  $-OH$ ,  $C_{1-2}$  alkoxy,  $C_{1-2}$  fluoroalkoxy, and  $-CN$ ; each  $R_5$  is independently F,  $-CN$ ,  $-OH$ ,  $C_{1-5}$  alkyl substituted with zero to 4  $R_g$ ,  $C_{1-2}$  alkoxy substituted with zero to 3  $R_g$ ,  $C_{2-3}$  alkenyl substituted with zero to 4  $R_g$ ,  $C_{2-3}$  alkynyl substituted with zero to 4  $R_g$ ,  $C_{3-4}$  cycloalkyl substituted with zero to 4  $R_g$ , phenyl substituted with zero to 3  $R_g$ , oxadiazolyl substituted with zero to 3  $R_g$ , pyridinyl substituted with zero to 3  $R_g$ ,  $-(CH_2)_{1-2}$ (heterocyclyl substituted with zero to 4  $R_g$ ),  $-(CH_2)_{1-2}NR_cC(O)(C_{1-4}$  alkyl),  $-(CH_2)_{1-2}NR_cC(O)O(C_{1-4}$  alkyl),  $-(CH_2)_{1-2}NR_cS(O)_2(C_{1-4}$  alkyl),  $-C(O)(C_{1-4}$  alkyl),  $-C(O)OH$ ,  $-C(O)O(C_{1-4}$  alkyl),  $-C(O)O(C_{3-4}$  cycloalkyl),  $-C(O)NR_aR_a$ , or  $-C(O)NR_a(C_{3-4}$  cycloalkyl), or two  $R_5$  attached to the same carbon atom form  $=O$ ; each  $R_6$  is H, F, or  $-CH_3$ ; and  $m$  is zero, 1, 2, or 3.

In one embodiment, a compound of Formula (I) or a salt thereof is provided wherein:  $R_1$  is H, F,  $-CN$ , or  $-OCH_3$ ;  $R_2$  is H,  $-CH_3$ ,  $-CH_2CN$ ,  $-CH_2CH_2F$ , or  $-CH_2CH=CH_2$ ;  $R_4$  is  $-CH_2R_{4a}$  or  $-CHR_{4a}R_{4b}$ ;  $R_{4a}$  is phenyl, naphthalenyl, or indolyl, each substituted with zero to 2 substituents independently selected from F,  $-CH_3$ ,  $-CH_2CH_3$ , and  $-OCH_3$ ;  $R_{4b}$  is phenyl or fluorophenyl; each  $R_5$  is  $-CH_3$ , or two  $R_5$  attached to the same carbon atom form  $=O$ ; and  $m$  is zero, 1, or 2.

In one embodiment, a compound of Formula (I) or a salt thereof is provided wherein  $R_1$  is H, F, Cl, Br,  $-CN$ ,  $C_{1-3}$  alkyl substituted with zero to 4  $R_{1a}$ , cyclopropyl substituted with zero to 3  $R_{1a}$ ,  $C_{1-3}$  alkoxy substituted with zero to 3  $R_{1a}$ ,  $-C(O)NR_aR_a$ ,  $-NR_aR_a$ ,  $-S(O)_nCH_3$ , or  $-P(O)(CH_3)_2$ . Included in this embodiment are compounds in which  $R_1$  is H, F, Cl, Br,  $-CN$ ,  $-CH_3$ ,  $-CHF_2$ ,  $-CF_3$ , cyclopropyl, or  $-OCH_3$ . Also included in this embodiment are compounds in which  $R_1$  is H, F,  $-CN$ , or  $-OCH_3$ .

In one embodiment, a compound of Formula (I) or a salt thereof is provided

wherein  $R_2$  is H,  $C_{1-2}$  alkyl substituted with zero to 2  $R_{2a}$ , or  $C_{2-3}$  alkenyl substituted with zero to 2  $R_{2a}$ . Included in this embodiment are compounds in which  $R_2$  is H,  $-CH_3$ ,  $-CH_2CN$ ,  $-CH_2CH_2F$ , or  $-CH_2CH=CH_2$ . Also included in this embodiment are compounds in which  $R_2$  is H,  $-CH_3$ ,  $-CH_2CN$ , or  $-CH_2CH_2F$ .

5 In one embodiment, a compound of Formula (I) or a salt thereof is provided wherein  $R_4$  is  $-CH_2R_{4a}$  or  $-CH_2CH_2R_{4a}$ . Included in this embodiment are compounds in which  $R_4$  is  $-CH_2R_{4a}$  or  $-CD_2R_{4a}$ .

In one embodiment, a compound of Formula (I) or a salt thereof is provided wherein  $R_4$  is  $-CH_2R_{4a}$ . Included in this embodiment are compounds in which  $R_4$  is  
10  $-CD_2R_{4a}$ .

In one embodiment, a compound of Formula (I) or a salt thereof is provided wherein  $R_4$  is  $-CHR_{4a}R_{4b}$  or  $-CR_{4a}R_{4b}R_{4c}$ .

In one embodiment, a compound of Formula (I) or a salt thereof is provided wherein  $R_4$  is  $-CHR_{4a}R_{4b}$ .

15 In one embodiment, a compound of Formula (I) or a salt thereof is provided wherein  $R_4$  is  $-CH_2R_{4a}$  or  $-CHR_{4a}R_{4b}$ .

In one embodiment, a compound of Formula (I) or a salt thereof is provided wherein  $m$  is 1, 2, or 3; and each  $R_5$  is independently F,  $-CN$ ,  $-OH$ ,  $C_{1-5}$  alkyl substituted with zero to 4  $R_g$ ,  $C_{1-2}$  alkoxy substituted with zero to 3  $R_g$ ,  $C_{2-3}$  alkenyl substituted with  
20 zero to 4  $R_g$ ,  $C_{2-3}$  alkynyl substituted with zero to 4  $R_g$ ,  $C_{3-4}$  cycloalkyl substituted with zero to 4  $R_g$ , phenyl substituted with zero to 3  $R_g$ , oxadiazolyl substituted with zero to 3  $R_g$ , pyridinyl substituted with zero to 3  $R_g$ ,  $-(CH_2)_{1-2}$ (heterocyclyl substituted with zero to 4  $R_g$ ),  $-(CH_2)_{1-2}NR_cC(O)(C_{1-4}$  alkyl),  $-(CH_2)_{1-2}NR_cC(O)O(C_{1-4}$  alkyl),  $-(CH_2)_{1-2}NR_cS(O)_2(C_{1-4}$  alkyl),  $-C(O)(C_{1-4}$  alkyl),  $-C(O)OH$ ,  $-C(O)O(C_{1-4}$  alkyl),  
25  $-C(O)O(C_{3-4}$  cycloalkyl),  $-C(O)NR_aR_a$ , or  $-C(O)NR_a(C_{3-4}$  cycloalkyl), or two  $R_5$  attached to the same carbon atom form  $=O$ . Included in this embodiment are compounds in which each  $R_5$  is independently F,  $-CN$ ,  $-OH$ ,  $C_{1-2}$  alkyl substituted with zero to 3  $R_g$ ,  $C_{1-2}$  alkoxy substituted with zero to 3  $R_g$ ,  $C_{3-4}$  cycloalkyl substituted with zero to 2  $R_g$ ,  $-C(O)(C_{1-4}$  alkyl),  $-C(O)OH$ ,  $-C(O)O(C_{1-2}$  alkyl), or  $-C(O)NR_aR_a$ , or two  $R_5$  attached to  
30 the same carbon atom form  $=O$ . Also included in this embodiment are compounds in

which each  $R_5$  is  $-\text{CH}_3$ , or two  $R_5$  attached to the same carbon atom form  $=\text{O}$ .

In one embodiment, a compound of Formula (I) or a salt thereof is provided wherein  $m$  is 2 and the two  $R_5$  are attached to the same carbon atom to form  $=\text{O}$ .


In one embodiment, a compound of Formula (I) or a salt thereof is provided  
5 wherein  $m$  is zero.

In one embodiment, a compound of Formula (I) or a salt thereof is provided wherein  $m$  is 1, 2, or 3. Included in this embodiment are compounds in which  $m$  is 1 or 2. Also included in this embodiment are compounds in which  $m$  is 1.

In one embodiment, a compound of Formula (I) or a salt thereof is provided  
10 wherein  $m$  is 2 or 3. Included in this embodiment are compounds in which  $m$  is 2.

In one embodiment, a compound of Formula (I) or a salt thereof is provided wherein  $m$  is 3.


In one embodiment, a compound of Formula (I) or a salt thereof is provided having the structure of Formula (II):



15

wherein one, two, or three of  $R_{5a}$ ,  $R_{5b}$ ,  $R_{5c}$ , and  $R_{5d}$  are each  $R_5$  and the remainder of  $R_{5a}$ ,  $R_{5b}$ ,  $R_{5c}$ , and  $R_{5d}$  are each hydrogen. Included in this embodiment are compounds in which each  $R_5$  is independently  $-\text{CN}$ ,  $-\text{CH}_3$ ,  $-\text{CH}_2\text{CH}_3$ ,  $-\text{CH}(\text{CH}_3)_2$ ,  $-\text{CHC}(\text{CH}_3)_2$ ,  $-\text{CH}_2\text{F}$ ,  $-\text{C}(\text{CH}_3)_2\text{F}$ ,  $-\text{CF}(\text{CH}_3)\text{CH}(\text{CH}_3)_2$ ,  $-\text{CH}_2\text{OH}$ ,  $-\text{C}(\text{CH}_3)_2\text{OH}$ ,  
20  $-\text{C}(\text{CH}_3)(\text{OH})\text{CH}(\text{CH}_3)_2$ ,  $-\text{CH}_2\text{OCH}_3$ ,  $-\text{C}(\text{O})\text{C}(\text{CH}_3)_2$ ,  $-\text{C}(\text{O})\text{OH}$ ,  $-\text{C}(\text{O})\text{OCH}_3$ ,  $-\text{C}(\text{O})\text{OC}(\text{CH}_3)_2$ ,  $-\text{C}(\text{O})\text{NH}_2$ ,  $-\text{C}(\text{O})\text{NH}(\text{cyclopropyl})$ ,  $-\text{C}(\text{O})\text{O}(\text{cyclopropyl})$ , cyclopropyl, phenyl, methyloxadiazolyl, or methylpyridinyl.

In one embodiment, a compound of Formula (I) or a salt thereof is provided having the structure of Formula (III):



In one embodiment, a compound of Formula (III) or a salt thereof is provided wherein  $R_{5a}$  is  $-\text{CH}_3$  and  $R_{5c}$  is  $-\text{CH}_3$ .

In one embodiment, a compound of Formula (III) or a salt thereof is provided  
5 wherein  $R_{5a}$  is  $-\text{CH}_3$  and  $R_{5c}$  is  $-\text{CH}_2\text{CH}_3$ .


In one embodiment, a compound of Formula (III) or a salt thereof is provided wherein  $R_{5a}$  is  $-\text{CH}_2\text{CH}_3$  and  $R_{5c}$  is  $-\text{CH}_3$ .


In one embodiment, a compound of Formula (III) or a salt thereof is provided wherein  $R_{5a}$  is  $-\text{CH}_2\text{CH}_3$  and  $R_{5c}$  is  $-\text{CH}_2\text{CH}_3$ .

10 In one embodiment, a compound of Formula (III) or a salt thereof is provided wherein  $R_{5a}$  is  $-\text{CH}_3$  and  $R_{5c}$  is  $-\text{CH}_2\text{OH}$ .


In one embodiment, a compound of Formula (III) or a salt thereof is provided wherein  $R_{5a}$  is  $-\text{CH}_3$  and  $R_{5c}$  is  $-\text{CH}_2\text{OCH}_3$ .
























15 In one embodiment, a compound of Formula (I) or a salt thereof is provided having the structure:







In one embodiment, a compound of Formula (I) or a salt thereof is provided wherein R<sub>4</sub> is:










In one embodiment, a compound of Formula (I) or a salt thereof is provided wherein R<sub>4</sub> is:





Included in this embodiment are compounds in which  $R_1$  is H, Br,  $-CN$ , or  $-OCH_3$ ; and  $R_2$  is  $-CH_3$ . Also included in this embodiment are compounds in which  $R_1$  is  $-CN$ ; and  $R_2$  is  $-CH_3$ .

5           The present invention may be embodied in other specific forms without departing from the spirit or essential attributes thereof. This invention encompasses all combinations of the aspects and/or embodiments of the invention noted herein. It is understood that any and all embodiments of the present invention may be taken in conjunction with any other embodiment or embodiments to describe additional  
10           embodiments. It is also to be understood that each individual element of the embodiments is meant to be combined with any and all other elements from any embodiment to describe an additional embodiment.

#### DEFINITIONS

15           The features and advantages of the invention may be more readily understood by those of ordinary skill in the art upon reading the following detailed description. It is to be appreciated that certain features of the invention that are, for clarity reasons, described above and below in the context of separate embodiments, may also be combined to form a single embodiment. Conversely, various features of the invention that are, for brevity  
20           reasons, described in the context of a single embodiment, may also be combined so as to form sub-combinations thereof. Embodiments identified herein as exemplary or preferred are intended to be illustrative and not limiting.

25           Unless specifically stated otherwise herein, references made in the singular may also include the plural. For example, “a” and “an” may refer to either one, or one or more.

30           As used herein, the phrase “compounds and/or salts thereof” refers to at least one compound, at least one salt of the compounds, or a combination thereof. For example, compounds of Formula (I) and/or salts thereof includes a compound of Formula (I); two compounds of Formula (I); a salt of a compound of Formula (I); a compound of Formula (I) and one or more salts of the compound of Formula (I); and two or more salts of a

compound of Formula (I).

Unless otherwise indicated, any atom with unsatisfied valences is assumed to have hydrogen atoms sufficient to satisfy the valences.

The definitions set forth herein take precedence over definitions set forth in any patent, patent application, and/or patent application publication incorporated herein by reference.

Listed below are definitions of various terms used to describe the present invention. These definitions apply to the terms as they are used throughout the specification (unless they are otherwise limited in specific instances) either individually or as part of a larger group.

Throughout the specification, groups and substituents thereof may be chosen by one skilled in the field to provide stable moieties and compounds.

In accordance with a convention used in the art,



is used in structural formulas herein to depict the bond that is the point of attachment of the moiety or substituent to the core or backbone structure.

The terms “halo” and “halogen,” as used herein, refer to F, Cl, Br, and I.

The term “cyano” refers to the group -CN.

The term “amino” refers to the group -NH<sub>2</sub>.

The term "oxo" refers to the group =O.

The term “alkyl” as used herein, refers to both branched and straight-chain saturated aliphatic hydrocarbon groups containing, for example, from 1 to 12 carbon atoms, from 1 to 6 carbon atoms, and from 1 to 4 carbon atoms. Examples of alkyl groups include, but are not limited to, methyl (Me), ethyl (Et), propyl (*e.g.*, *n*-propyl and *i*-propyl), butyl (*e.g.*, *n*-butyl, *i*-butyl, *sec*-butyl, and *t*-butyl), and pentyl (*e.g.*, *n*-pentyl, isopentyl, neopentyl), *n*-hexyl, 2-methylpentyl, 2-ethylbutyl, 3-methylpentyl, and 4-methylpentyl. When numbers appear in a subscript after the symbol “C”, the subscript defines with more specificity the number of carbon atoms that a particular group may contain. For example, “C<sub>1-4</sub> alkyl” denotes straight and branched chain alkyl groups with one to four carbon atoms.

The term "fluoroalkyl" as used herein is intended to include both branched and

straight-chain saturated aliphatic hydrocarbon groups substituted with one or more fluorine atoms. For example, "C<sub>1-4</sub> fluoroalkyl" is intended to include C<sub>1</sub>, C<sub>2</sub>, C<sub>3</sub>, and C<sub>4</sub> alkyl groups substituted with one or more fluorine atoms. Representative examples of fluoroalkyl groups include, but are not limited to, -CF<sub>3</sub> and -CH<sub>2</sub>CF<sub>3</sub>.

5           The term "hydroxyalkyl" includes both branched and straight-chain saturated alkyl groups substituted with one or more hydroxyl groups. For example, "hydroxyalkyl" includes -CH<sub>2</sub>OH, -CH<sub>2</sub>CH<sub>2</sub>OH, and C<sub>1-4</sub> hydroxyalkyl.

          The term "alkenyl" refers to a straight or branched chain hydrocarbon radical containing from 2 to 12 carbon atoms and at least one carbon-carbon double bond.  
10       Exemplary such groups include ethenyl or allyl. For example, "C<sub>2-6</sub> alkenyl" denotes straight and branched chain alkenyl groups with two to six carbon atoms.

          The term "alkynyl" refers to a straight or branched chain hydrocarbon radical containing from 2 to 12 carbon atoms and at least one carbon to carbon triple bond. Exemplary such groups include ethynyl. For example, "C<sub>2-6</sub> alkynyl" denotes straight and  
15       branched chain alkynyl groups with two to six carbon atoms.

          The term "cycloalkyl," as used herein, refers to a group derived from a non-aromatic monocyclic or polycyclic hydrocarbon molecule by removal of one hydrogen atom from a saturated ring carbon atom. Representative examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclopentyl, and cyclohexyl. When numbers  
20       appear in a subscript after the symbol "C", the subscript defines with more specificity the number of carbon atoms that a particular cycloalkyl group may contain. For example, "C<sub>3-6</sub> cycloalkyl" denotes cycloalkyl groups with three to six carbon atoms.

          The term "fluorocycloalkyl" as used herein is intended to include a cycloalkyl group substituted with one or more fluorine atoms.

25       The term "alkoxy," as used herein, refers to an alkyl group attached to the parent molecular moiety through an oxygen atom, for example, methoxy group (-OCH<sub>3</sub>). For example, "C<sub>1-3</sub> alkoxy" denotes alkoxy groups with one to three carbon atoms.

          The terms "fluoroalkoxy" and "-O(fluoroalkyl)" represent a fluoroalkyl group as defined above attached through an oxygen linkage (-O-). For example, "C<sub>1-4</sub>  
30       fluoroalkoxy" is intended to include C<sub>1</sub>, C<sub>2</sub>, C<sub>3</sub>, and C<sub>4</sub> fluoroalkoxy groups.

          The terms "carbocyclo", "carbocyclic" or "carbocyclyl" may be used interchangeably and refer to cyclic groups having at least one saturated or partially

saturated non-aromatic ring wherein all atoms of all rings are carbon. The carbocyclyl ring may be unsubstituted or may contain one or more substituents as valence allows. Thus, the term includes nonaromatic rings such as for example, cycloalkyl, cycloalkenyl, and cycloalkynyl rings. Exemplary bicyclic carbocyclyl groups include, indanyl, indenyl, 5 dihydronaphthalenyl, tetrahydronaphthenyl, hexahydronaphthalenyl, octahydronaphthalenyl, decahydronaphthalenyl, bicycloheptanyl, bicyclooctanyl, and bicyclononanyl.

The term “aryl” as used herein, refers to a group of atoms derived from a molecule containing aromatic ring(s) by removing one hydrogen that is bonded to the aromatic 10 ring(s). Representative examples of aryl groups include, but are not limited to, phenyl and naphthyl. The aryl ring may be unsubstituted or may contain one or more substituents as valence allows.

The term “benzyl,” as used herein, refers to a methyl group in which one of the hydrogen atoms is replaced by a phenyl group. The phenyl ring may be unsubstituted or 15 may contain one or more substituents as valence allows.

The term “heteroatom” refers to oxygen (O), sulfur (S), and nitrogen (N).

The terms “heterocyclo”, “heterocyclic”, or “heterocyclyl” may be used interchangeably and refer to cyclic groups having at least one saturated or partially saturated non-aromatic ring and wherein one or more of the rings have at least one 20 heteroatom (O, S or N), said heteroatom containing ring preferably having 1 to 3 heteroatoms independently selected from O, S, and/or N. The ring of such a group containing a heteroatom can contain one or two oxygen or sulfur atoms and/or from one to four nitrogen atoms provided that the total number of heteroatoms in each ring is four or less, and further provided that the ring contains at least one carbon atom. The nitrogen 25 and sulfur atoms may optionally be oxidized and the nitrogen atoms may optionally be quaternized. The heterocyclo group may be attached at any available nitrogen or carbon atom. The heterocyclo ring may be unsubstituted or may contain one or more substituents as valence allows.

Exemplary monocyclic heterocyclyl groups include pyrrolidinyl, imidazoliny, 30 oxazolidinyl, isoxazoliny, thiazolidinyl, isothiazolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, 2-oxoazepinyl, azepinyl, 4-piperidonyl, tetrahydropyranyl, morpholinyl, thiamorpholinyl,

thiamorpholinyl sulfoxide, thiamorpholinyl sulfone, 1,3-dioxolane, tetrahydro-1,1-dioxothienyl, dihydroisoindolyl, and tetrahydroquinolyl

The term “heteroaryl” refers to substituted and unsubstituted aromatic 5- or 6-membered monocyclic groups and 9- or 10-membered bicyclic groups that have at least one heteroatom (O, S or N) in at least one of the rings, said heteroatom-containing ring preferably having 1, 2, or 3 heteroatoms independently selected from O, S, and/or N. Each ring of the heteroaryl group containing a heteroatom can contain one or two oxygen or sulfur atoms and/or from one to four nitrogen atoms provided that the total number of heteroatoms in each ring is four or less and each ring has at least one carbon atom. The fused rings completing the bicyclic group are aromatic and may contain only carbon atoms. The nitrogen and sulfur atoms may optionally be oxidized and the nitrogen atoms may optionally be quaternized. Bicyclic heteroaryl groups must include only aromatic rings. The heteroaryl group may be attached at any available nitrogen or carbon atom of any ring. The heteroaryl ring system may be unsubstituted or may contain one or more substituents.

Exemplary monocyclic heteroaryl groups include pyrrolyl, pyrazolyl, pyrazolinyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, isothiazolyl, furanyl, thiophenyl, oxadiazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, and triazinyl.

Exemplary bicyclic heteroaryl groups include indolyl, benzothiazolyl, benzodioxolyl, benzoxazolyl, benzothienyl, quinolyl, tetrahydroisoquinolyl, isoquinolyl, benzimidazolyl, benzopyranyl, indolizyl, benzofuranyl, chromonyl, coumarinyl, benzopyranyl, cinnolyl, quinoxalinyl, indazolyl, and pyrrolopyridyl.

The phrase “pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.

The compounds of Formula (I) can form salts which are also within the scope of this invention. Unless otherwise indicated, reference to an inventive compound is understood to include reference to one or more salts thereof. The term “salt(s)” denotes acidic and/or basic salts formed with inorganic and/or organic acids and bases. In addition, the term “salt(s)” may include zwitterions (inner salts), *e.g.*, when a compound of

Formula (I) contains both a basic moiety, such as an amine or a pyridine or imidazole ring, and an acidic moiety, such as a carboxylic acid. Pharmaceutically acceptable (*i.e.*, non-toxic, physiologically acceptable) salts are preferred, such as, for example, acceptable metal and amine salts in which the cation does not contribute significantly to the toxicity or biological activity of the salt. However, other salts may be useful, *e.g.*, in isolation or purification steps which may be employed during preparation, and thus, are contemplated within the scope of the invention. Salts of the compounds of the formula (I) may be formed, for example, by reacting a compound of the Formula (I) with an amount of acid or base, such as an equivalent amount, in a medium such as one in which the salt precipitates or in an aqueous medium followed by lyophilization.

Exemplary acid addition salts include acetates (such as those formed with acetic acid or trihaloacetic acid, for example, trifluoroacetic acid), adipates, alginates, ascorbates, aspartates, benzoates, benzenesulfonates, bisulfates, borates, butyrates, citrates, camphorates, camphorsulfonates, cyclopentanepropionates, digluconates, dodecylsulfates, ethanesulfonates, fumarates, glucoheptanoates, glycerophosphates, hemisulfates, heptanoates, hexanoates, hydrochlorides (formed with hydrochloric acid), hydrobromides (formed with hydrogen bromide), hydroiodides, maleates (formed with maleic acid), 2-hydroxyethanesulfonates, lactates, methanesulfonates (formed with methanesulfonic acid), 2-naphthalenesulfonates, nicotines, nitrates, oxalates, pectinates, persulfates, 3-phenylpropionates, phosphates, picrates, pivalates, propionates, salicylates, succinates, sulfates (such as those formed with sulfuric acid), sulfonates (such as those mentioned herein), tartrates, thiocyanates, toluenesulfonates such as tosylates, undecanoates, and the like.

Exemplary basic salts include ammonium salts, alkali metal salts such as sodium, lithium, and potassium salts; alkaline earth metal salts such as calcium and magnesium salts; barium, zinc, and aluminum salts; salts with organic bases (for example, organic amines) such as trialkylamines such as triethylamine, procaine, dibenzylamine, N-benzyl- $\beta$ -phenethylamine, 1-phenamine, N,N'-dibenzylethylene-diamine, dehydroabietylamine, N-ethylpiperidine, benzylamine, dicyclohexylamine or similar pharmaceutically acceptable amines and salts with amino acids such as arginine, lysine and the like. Basic nitrogen-containing groups may be quaternized with agents such as lower alkyl halides (*e.g.*, methyl, ethyl, propyl, and butyl chlorides, bromides and iodides), dialkyl sulfates

(*e.g.*, dimethyl, diethyl, dibutyl, and diamyl sulfates), long chain halides (*e.g.*, decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides), aralkyl halides (*e.g.*, benzyl and phenethyl bromides), and others. Preferred salts include monohydrochloride, hydrogensulfate, methanesulfonate, phosphate or nitrate salts.

5           The compounds of Formula (I) can be provided as amorphous solids or crystalline solids. Lyophilization can be employed to provide the compounds of Formula (I) as a solid.

          It should further be understood that solvates (*e.g.*, hydrates) of the Compounds of Formula (I) are also within the scope of the present invention. The term “solvate” means  
10       a physical association of a compound of Formula (I) with one or more solvent molecules, whether organic or inorganic. This physical association includes hydrogen bonding. In certain instances the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid. “Solvate” encompasses both solution-phase and isolable solvates. Exemplary solvates include  
15       hydrates, ethanolates, methanolates, isopropanolates, acetonitrile solvates, and ethyl acetate solvates. Methods of solvation are known in the art.

          Various forms of prodrugs are known in the art and are described in Rautio, J. et al., *Nature Review Drug Discovery*, 17, 559-587 (2018).

          In addition, compounds of Formula (I), subsequent to their preparation, can be  
20       isolated and purified to obtain a composition containing an amount by weight equal to or greater than 99% of a compound of Formula (I) (“substantially pure”), which is then used or formulated as described herein. Such “substantially pure” compounds of Formula (I) are also contemplated herein as part of the present invention.

          “Stable compound” and “stable structure” are meant to indicate a compound that  
25       is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent. The present invention is intended to embody stable compounds.

          “Therapeutically effective amount” is intended to include an amount of a  
30       compound of the present invention alone or an amount of the combination of compounds claimed or an amount of a compound of the present invention in combination with other active ingredients effective to act as an inhibitor of DGK $\alpha$  and/or DGK $\zeta$ , or effective to treat or prevent viral infections and proliferative disorders, such as cancer.

As used herein, “treating” or “treatment” cover the treatment of a disease-state in a mammal, particularly in a human, and include: (a) preventing the disease-state from occurring in a mammal, in particular, when such mammal is predisposed to the disease-state but has not yet been diagnosed as having it; (b) inhibiting the disease-state, i.e.,  
5 arresting its development; and/or (c) relieving the disease-state, i.e., causing regression of the disease state.

The compounds of the present invention are intended to include all isotopes of atoms occurring in the present compounds. Isotopes include those atoms having the same atomic number but different mass numbers. By way of general example and without  
10 limitation, isotopes of hydrogen include deuterium (D) and tritium (T). Isotopes of carbon include  $^{13}\text{C}$  and  $^{14}\text{C}$ . Isotopically-labeled compounds of the invention can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described herein, using an appropriate isotopically-labeled reagent in place of the non-labeled reagent otherwise employed.

15 Compounds in accordance with Formula (I) and/or pharmaceutically acceptable salts thereof can be administered by any means suitable for the condition to be treated, which can depend on the need for site-specific treatment or quantity of Formula (I) compound to be delivered.

Also embraced within this invention is a class of pharmaceutical compositions  
20 comprising a compound of Formula (I) and/or pharmaceutically acceptable salts thereof; and one or more non-toxic, pharmaceutically-acceptable carriers and/or diluents and/or adjuvants (collectively referred to herein as “carrier” materials) and, if desired, other active ingredients. The compounds of Formula (I) may be administered by any suitable route, preferably in the form of a pharmaceutical composition adapted to such a route, and  
25 in a dose effective for the treatment intended. The compounds and compositions of the present invention may, for example, be administered orally, mucosally, or parentally including intravascularly, intravenously, intraperitoneally, subcutaneously, intramuscularly, and intrasternally in dosage unit formulations containing conventional pharmaceutically acceptable carriers, adjuvants, and vehicles. For example, the  
30 pharmaceutical carrier may contain a mixture of mannitol or lactose and microcrystalline cellulose. The mixture may contain additional components such as a lubricating agent, e.g. magnesium stearate and a disintegrating agent such as crospovidone. The carrier

mixture may be filled into a gelatin capsule or compressed as a tablet. The pharmaceutical composition may be administered as an oral dosage form or an infusion, for example.

For oral administration, the pharmaceutical composition may be in the form of, for example, a tablet, capsule, liquid capsule, suspension, or liquid. The pharmaceutical composition is preferably made in the form of a dosage unit containing a particular amount of the active ingredient. For example, the pharmaceutical composition may be provided as a tablet or capsule comprising an amount of active ingredient in the range of from about 0.1 to 1000 mg, preferably from about 0.25 to 250 mg, and more preferably from about 0.5 to 100 mg. A suitable daily dose for a human or other mammal may vary widely depending on the condition of the patient and other factors, but, can be determined using routine methods.

Any pharmaceutical composition contemplated herein can, for example, be delivered orally via any acceptable and suitable oral preparations. Exemplary oral preparations, include, but are not limited to, for example, tablets, troches, lozenges, aqueous and oily suspensions, dispersible powders or granules, emulsions, hard and soft capsules, liquid capsules, syrups, and elixirs. Pharmaceutical compositions intended for oral administration can be prepared according to any methods known in the art for manufacturing pharmaceutical compositions intended for oral administration. In order to provide pharmaceutically palatable preparations, a pharmaceutical composition in accordance with the invention can contain at least one agent selected from sweetening agents, flavoring agents, coloring agents, demulcents, antioxidants, and preserving agents.

A tablet can, for example, be prepared by admixing at least one compound of Formula (I) and/or at least one pharmaceutically acceptable salt thereof with at least one non-toxic pharmaceutically acceptable excipient suitable for the manufacture of tablets. Exemplary excipients include, but are not limited to, for example, inert diluents, such as, for example, calcium carbonate, sodium carbonate, lactose, calcium phosphate, and sodium phosphate; granulating and disintegrating agents, such as, for example, microcrystalline cellulose, sodium crosscarmellose, corn starch, and alginic acid; binding agents, such as, for example, starch, gelatin, polyvinyl-pyrrolidone, and acacia; and lubricating agents, such as, for example, magnesium stearate, stearic acid, and talc. Additionally, a tablet can either be uncoated, or coated by known techniques to either

mask the bad taste of an unpleasant tasting drug, or delay disintegration and absorption of the active ingredient in the gastrointestinal tract thereby sustaining the effects of the active ingredient for a longer period. Exemplary water soluble taste masking materials, include, but are not limited to, hydroxypropyl-methylcellulose and hydroxypropyl-  
5 cellulose. Exemplary time delay materials, include, but are not limited to, ethyl cellulose and cellulose acetate butyrate.

Hard gelatin capsules can, for example, be prepared by mixing at least one compound of Formula (I) and/or at least one salt thereof with at least one inert solid diluent, such as, for example, calcium carbonate; calcium phosphate; and kaolin.

10 Soft gelatin capsules can, for example, be prepared by mixing at least one compound of Formula (I) and/or at least one pharmaceutically acceptable salt thereof with at least one water soluble carrier, such as, for example, polyethylene glycol; and at least one oil medium, such as, for example, peanut oil, liquid paraffin, and olive oil.

An aqueous suspension can be prepared, for example, by admixing at least one  
15 compound of Formula (I) and/or at least one pharmaceutically acceptable salt thereof with at least one excipient suitable for the manufacture of an aqueous suspension. Exemplary excipients suitable for the manufacture of an aqueous suspension, include, but are not limited to, for example, suspending agents, such as, for example, sodium  
20 carboxymethylcellulose, methylcellulose, hydroxypropylmethyl-cellulose, sodium alginate, alginic acid, polyvinyl-pyrrolidone, gum tragacanth, and gum acacia; dispersing or wetting agents, such as, for example, a naturally-occurring phosphatide, e.g., lecithin; condensation products of alkylene oxide with fatty acids, such as, for example, polyoxyethylene stearate; condensation products of ethylene oxide with long chain  
25 aliphatic alcohols, such as, for example heptadecaethylene-oxycetanol; condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol, such as, for example, polyoxyethylene sorbitol monooleate; and condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, such as, for example, polyethylene sorbitan monooleate. An aqueous suspension can also contain  
30 at least one preservative, such as, for example, ethyl and n-propyl p-hydroxybenzoate; at least one coloring agent; at least one flavoring agent; and/or at least one sweetening agent, including but not limited to, for example, sucrose, saccharin, and aspartame.

Oily suspensions can, for example, be prepared by suspending at least one

compound of Formula (I) and/or at least one pharmaceutically acceptable salt thereof in either a vegetable oil, such as, for example, arachis oil; olive oil; sesame oil; and coconut oil; or in mineral oil, such as, for example, liquid paraffin. An oily suspension can also contain at least one thickening agent, such as, for example, beeswax; hard paraffin; and  
5 cetyl alcohol. In order to provide a palatable oily suspension, at least one of the sweetening agents already described hereinabove, and/or at least one flavoring agent can be added to the oily suspension. An oily suspension can further contain at least one preservative, including, but not limited to, for example, an anti-oxidant, such as, for example, butylated hydroxyanisol, and alpha-tocopherol.

10 Dispersible powders and granules can, for example, be prepared by admixing at least one compound of Formula (I) and/or at least one pharmaceutically acceptable salt thereof with at least one dispersing and/or wetting agent; at least one suspending agent; and/or at least one preservative. Suitable dispersing agents, wetting agents, and suspending agents are as already described above. Exemplary preservatives include, but  
15 are not limited to, for example, anti-oxidants, e.g., ascorbic acid. In addition, dispersible powders and granules can also contain at least one excipient, including, but not limited to, for example, sweetening agents; flavoring agents; and coloring agents.

An emulsion of at least one compound of Formula (I) and/or at least one pharmaceutically acceptable salt thereof can, for example, be prepared as an oil-in-water  
20 emulsion. The oily phase of the emulsions comprising compounds of Formula (I) may be constituted from known ingredients in a known manner. The oil phase can be provided by, but is not limited to, for example, a vegetable oil, such as, for example, olive oil and arachis oil; a mineral oil, such as, for example, liquid paraffin; and mixtures thereof. While the phase may comprise merely an emulsifier, it may comprise a mixture of at least  
25 one emulsifier with a fat or an oil or with both a fat and an oil. Suitable emulsifying agents include, but are not limited to, for example, naturally-occurring phosphatides, e.g., soy bean lecithin; esters or partial esters derived from fatty acids and hexitol anhydrides, such as, for example, sorbitan monooleate; and condensation products of partial esters with ethylene oxide, such as, for example, polyoxyethylene sorbitan monooleate.  
30 Preferably, a hydrophilic emulsifier is included together with a lipophilic emulsifier which acts as a stabilizer. It is also preferred to include both an oil and a fat. Together, the emulsifier(s) with or without stabilizer(s) make-up the so-called emulsifying wax, and

the wax together with the oil and fat make up the so-called emulsifying ointment base which forms the oily dispersed phase of the cream formulations. An emulsion can also contain a sweetening agent, a flavoring agent, a preservative, and/or an antioxidant. Emulsifiers and emulsion stabilizers suitable for use in the formulation of the present invention include Tween 60, Span 80, cetostearyl alcohol, myristyl alcohol, glyceryl monostearate, sodium lauryl sulfate, glyceryl distearate alone or with a wax, or other materials well known in the art.

The compounds of Formula (I) and/or at least one pharmaceutically acceptable salt thereof can, for example, also be delivered intravenously, subcutaneously, and/or intramuscularly via any pharmaceutically acceptable and suitable injectable form. Exemplary injectable forms include, but are not limited to, for example, sterile aqueous solutions comprising acceptable vehicles and solvents, such as, for example, water, Ringer's solution, and isotonic sodium chloride solution; sterile oil-in-water microemulsions; and aqueous or oleaginous suspensions.

Formulations for parenteral administration may be in the form of aqueous or non-aqueous isotonic sterile injection solutions or suspensions. These solutions and suspensions may be prepared from sterile powders or granules using one or more of the carriers or diluents mentioned for use in the formulations for oral administration or by using other suitable dispersing or wetting agents and suspending agents. The compounds may be dissolved in water, polyethylene glycol, propylene glycol, ethanol, corn oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodium chloride, tragacanth gum, and/or various buffers. Other adjuvants and modes of administration are well and widely known in the pharmaceutical art. The active ingredient may also be administered by injection as a composition with suitable carriers including saline, dextrose, or water, or with cyclodextrin (i.e. Captisol), cosolvent solubilization (i.e. propylene glycol) or micellar solubilization (i.e. Tween 80).

The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed, including synthetic

mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.

A sterile injectable oil-in-water microemulsion can, for example, be prepared by 1) dissolving at least one compound of Formula (I) in an oily phase, such as, for example, a mixture of soybean oil and lecithin; 2) combining the Formula (I) containing oil phase with a water and glycerol mixture; and 3) processing the combination to form a microemulsion.

A sterile aqueous or oleaginous suspension can be prepared in accordance with methods already known in the art. For example, a sterile aqueous solution or suspension can be prepared with a non-toxic parenterally-acceptable diluent or solvent, such as, for example, 1,3-butane diol; and a sterile oleaginous suspension can be prepared with a sterile non-toxic acceptable solvent or suspending medium, such as, for example, sterile fixed oils, e.g., synthetic mono- or diglycerides; and fatty acids, such as, for example, oleic acid.

Pharmaceutically acceptable carriers, adjuvants, and vehicles that may be used in the pharmaceutical compositions of this invention include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, self-emulsifying drug delivery systems (SEDDS) such as d-alpha-tocopherol polyethyleneglycol 1000 succinate, surfactants used in pharmaceutical dosage forms such as Tweens, polyethoxylated castor oil such as CREMOPHOR surfactant (BASF), or other similar polymeric delivery matrices, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat. Cyclodextrins such as alpha-, beta-, and gamma-cyclodextrin, or chemically modified derivatives such as hydroxyalkylcyclodextrins, including 2- and 3-hydroxypropyl-cyclodextrins, or other solubilized derivatives may also be advantageously used to enhance delivery of compounds of the formulae described herein.

The pharmaceutically active compounds of this invention can be processed in

accordance with conventional methods of pharmacy to produce medicinal agents for administration to patients, including humans and other mammals. The pharmaceutical compositions may be subjected to conventional pharmaceutical operations such as sterilization and/or may contain conventional adjuvants, such as preservatives, stabilizers, wetting agents, emulsifiers, buffers etc. Tablets and pills can additionally be prepared with enteric coatings. Such compositions may also comprise adjuvants, such as wetting, sweetening, flavoring, and perfuming agents.

The amounts of compounds that are administered and the dosage regimen for treating a disease condition with the compounds and/or compositions of this invention depends on a variety of factors, including the age, weight, sex, the medical condition of the subject, the type of disease, the severity of the disease, the route and frequency of administration, and the particular compound employed. Thus, the dosage regimen may vary widely, but can be determined routinely using standard methods. A daily dose of about 0.001 to 100 mg/kg body weight, preferably between about 0.0025 and about 50 mg/kg body weight and most preferably between about 0.005 to 10 mg/kg body weight, may be appropriate. The daily dose can be administered in one to four doses per day. Other dosing schedules include one dose per week and one dose per two day cycle.

For therapeutic purposes, the active compounds of this invention are ordinarily combined with one or more adjuvants appropriate to the indicated route of administration. If administered orally, the compounds may be admixed with lactose, sucrose, starch powder, cellulose esters of alkanolic acids, cellulose alkyl esters, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulfuric acids, gelatin, acacia gum, sodium alginate, polyvinylpyrrolidone, and/or polyvinyl alcohol, and then tableted or encapsulated for convenient administration. Such capsules or tablets may contain a controlled-release formulation as may be provided in a dispersion of active compound in hydroxypropylmethyl cellulose.

Pharmaceutical compositions of this invention comprise at least one compound of Formula (I) and/or at least one pharmaceutically acceptable salt thereof, and optionally an additional agent selected from any pharmaceutically acceptable carrier, adjuvant, and vehicle. Alternate compositions of this invention comprise a compound of the Formula (I) described herein, or a prodrug thereof, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

## UTILITY

The compounds of Formula (I) are useful for the treatment of cancer.

In another embodiment, the present invention provides a combined preparation of  
5 a compound of Formula (I), and/or a pharmaceutically acceptable salt thereof, a  
stereoisomer thereof or a tautomer thereof, and additional therapeutic agent(s) for  
simultaneous, separate or sequential use in the treatment and/or prophylaxis of multiple  
diseases or disorders associated with DGK target inhibition in T cells.

In another aspect, the invention provides a method of treating a patient suffering  
10 from or susceptible to a medical condition that is associated with DGK target inhibition in  
T cells. A number of medical conditions can be treated. The method comprises  
administering to the patient a therapeutically effective amount of a composition  
comprising a compound of Formula (I) and/or a pharmaceutically acceptable salt thereof,  
a stereoisomer thereof or a tautomer thereof. For example, the compounds described  
15 herein may be used to treat or prevent viral infections and proliferative diseases such as  
cancer.

The compounds for Formula (I) and pharmaceutical compositions comprising at  
least one compound of Formula (I) are useful in treating or preventing any disease or  
conditions that are associated with DGK target inhibition in T cells. These include viral  
20 and other infections (*e.g.*, skin infections, GI infection, urinary tract infections, genito-  
urinary infections, systemic infections), and proliferative diseases (*e.g.*, cancer). The  
compounds of Formula (I) and pharmaceutical compositions comprising in at least one  
compound of Formula (I) may be administered to animals, preferably mammals (*e.g.*,  
domesticated animals, cats, dogs, mice, rats), and more preferably humans. Any method  
25 of administration may be used to deliver the compound or pharmaceutical composition to  
the patient. In certain embodiments, the compound of Formula (I) or pharmaceutical  
composition comprising at least compound of Formula (I) is administered orally. In other  
embodiments, the Formula (I) or pharmaceutical composition comprising at least  
compound of Formula (I) is administered parenterally.

30 The compounds of Formula (I) can inhibit activity of the diacylglycerol kinase  
alpha and zeta (DGK $\alpha/\zeta$ ). For example, the compounds of Formula (I) can be used to  
inhibit activity of DGK $\alpha$  and DGK $\zeta$  in a cell or in an individual in need of modulation of

DGK $\alpha$  and DGK $\zeta$  by administering an inhibiting amount of a compound of Formula (I) or a salt thereof.

The present invention further provides methods of treating diseases associated with activity or expression, including abnormal activity and/or overexpression, of DGK $\alpha$  and DGK $\zeta$  in an individual (*e.g.*, patient) by administering to the individual in need of such treatment a therapeutically effective amount or dose of a compound of Formula (I) or a pharmaceutical composition thereof. Example diseases can include any disease, disorder or condition that is directly or indirectly linked to expression or activity of DGK $\alpha$  and DGK $\zeta$  enzyme, such as over expression or abnormal activity. A DGK $\alpha$  and DGK $\zeta$  -associated disease can also include any disease, disorder or condition that can be prevented, ameliorated, or cured by modulating DGK $\alpha$  and DGK $\zeta$  enzyme activity. Examples of DGK $\alpha$  and DGK $\zeta$  associated diseases include cancer and viral infections such as HIV infection, hepatitis B, and hepatitis C.

In one aspect, the compound(s) of Formula (I) are sequentially administered prior to administration of the immuno-oncology agent. In another aspect, compound(s) of Formula (I) are administered concurrently with the immuno-oncology agent. In yet another aspect, compound(s) of Formula (I) are sequentially administered after administration of the immuno-oncology agent.

In another aspect, compounds of Formula (I) may be co-formulated with an immuno-oncology agent.

Immuno-oncology agents include, for example, a small molecule drug, antibody, or other biologic or small molecule. Examples of biologic immuno-oncology agents include, but are not limited to, cancer vaccines, antibodies, and cytokines. In one aspect, the antibody is a monoclonal antibody. In another aspect, the monoclonal antibody is humanized or human.

In one aspect, the immuno-oncology agent is (i) an agonist of a stimulatory (including a co-stimulatory) receptor or (ii) an antagonist of an inhibitory (including a co-inhibitory) signal on T cells, both of which result in amplifying antigen-specific T cell responses (often referred to as immune checkpoint regulators).

Certain of the stimulatory and inhibitory molecules are members of the immunoglobulin super family (IgSF). One important family of membrane-bound ligands

that bind to co-stimulatory or co-inhibitory receptors is the B7 family, which includes B7-1, B7-2, B7-H1 (PD-L1), B7-DC (PD-L2), B7-H2 (ICOS-L), B7-H3, B7-H4, B7-H5 (VISTA), and B7-H6. Another family of membrane bound ligands that bind to co-stimulatory or co-inhibitory receptors is the TNF family of molecules that bind to cognate  
5 TNF receptor family members, which includes CD40 and CD40L, OX-40, OX-40L, CD70, CD27L, CD30, CD30L, 4-1BBL, CD137 (4-1BB), TRAIL/Apo2-L, TRAILR1/DR4, TRAILR2/DR5, TRAILR3, TRAILR4, OPG, RANK, RANKL, TWEAKR/Fn14, TWEAK, BAFFR, EDAR, XEDAR, TACI, APRIL, BCMA, LT $\beta$ R, LIGHT, DcR3, HVEM, VEGI/TL1A, TRAMP/DR3, EDAR, EDA1, XEDAR, EDA2,  
10 TNFR1, Lymphotoxin  $\alpha$ /TNF $\beta$ , TNFR2, TNF $\alpha$ , LT $\beta$ R, Lymphotoxin  $\alpha$  1 $\beta$ 2, FAS, FASL, RELT, DR6, TROY, NGFR.

In one aspect, T cell responses can be stimulated by a combination of a compound of Formula (I) and one or more of (i) an antagonist of a protein that inhibits T cell activation (e.g., immune checkpoint inhibitors) such as CTLA-4, PD-1, PD-L1, PD-L2,  
15 LAG-3, TIM-3, Galectin 9, CEACAM-1, BTLA, CD69, Galectin-1, TIGIT, CD113, GPR56, VISTA, 2B4, CD48, GARP, PD1H, LAIR1, TIM-1, and TIM-4, and (ii) an agonist of a protein that stimulates T cell activation such as B7-1, B7-2, CD28, 4-1BB (CD137), 4-1BBL, ICOS, ICOS-L, OX40, OX40L, GITR, GITRL, CD70, CD27, CD40, DR3 and CD28H.

20 Other agents that can be combined with compounds of Formula (I) for the treatment of cancer include antagonists of inhibitory receptors on NK cells or agonists of activating receptors on NK cells. For example, compounds of Formula (I) can be combined with antagonists of KIR, such as lirilumab.

Yet other agents for combination therapies include agents that inhibit or deplete  
25 macrophages or monocytes, including but not limited to CSF-1R antagonists such as CSF-1R antagonist antibodies including RG7155 (WO11/70024, WO11/107553, WO11/131407, WO13/87699, WO13/119716, WO13/132044) or FPA-008 (WO11/140249; WO13169264; WO14/036357).

In another aspect, compounds of Formula (I) can be used with one or more of  
30 agonistic agents that ligate positive costimulatory receptors, blocking agents that attenuate signaling through inhibitory receptors, antagonists, and one or more agents that increase systemically the frequency of anti-tumor T cells, agents that overcome distinct

immune suppressive pathways within the tumor microenvironment (e.g., block inhibitory receptor engagement (e.g., PD-L1/PD-1 interactions), deplete or inhibit Tregs (e.g., using an anti-CD25 monoclonal antibody (e.g., daclizumab) or by ex vivo anti-CD25 bead depletion), inhibit metabolic enzymes such as IDO, or reverse/prevent T cell anergy or exhaustion) and agents that trigger innate immune activation and/or inflammation at tumor sites.

In one aspect, the immuno-oncology agent is a CTLA-4 antagonist, such as an antagonistic CTLA-4 antibody. Suitable CTLA-4 antibodies include, for example, YERVOY (ipilimumab) or tremelimumab.

In another aspect, the immuno-oncology agent is a PD-1 antagonist, such as an antagonistic PD-1 antibody. Suitable PD-1 antibodies include, for example, OPDIVO (nivolumab), KEYTRUDA (pembrolizumab), or MEDI-0680 (AMP-514; WO2012/145493). The immuno-oncology agent may also include pidilizumab (CT-011), though its specificity for PD-1 binding has been questioned. Another approach to target the PD-1 receptor is the recombinant protein composed of the extracellular domain of PD-L2 (B7-DC) fused to the Fc portion of IgG1, called AMP-224

In another aspect, the immuno-oncology agent is a PD-L1 antagonist, such as an antagonistic PD-L1 antibody. Suitable PD-L1 antibodies include, for example, MPDL3280A (RG7446; WO2010/077634), durvalumab (MEDI4736), BMS-936559 (WO2007/005874), and MSB0010718C (WO2013/79174).

In another aspect, the immuno-oncology agent is a LAG-3 antagonist, such as an antagonistic LAG-3 antibody. Suitable LAG3 antibodies include, for example, BMS-986016 (WO10/19570, WO14/08218), or IMP-731 or IMP-321 (WO08/132601, WO09/44273).

In another aspect, the immuno-oncology agent is a CD137 (4-1BB) agonist, such as an agonistic CD137 antibody. Suitable CD137 antibodies include, for example, urelumab and PF-05082566 (WO12/32433).

In another aspect, the immuno-oncology agent is a GITR agonist, such as an agonistic GITR antibody. Suitable GITR antibodies include, for example, BMS-986153, BMS-986156, TRX-518 (WO06/105021, WO09/009116) and MK-4166 (WO11/028683).

In another aspect, the immuno-oncology agent is an IDO antagonist. Suitable IDO antagonists include, for example, INCB-024360 (WO2006/122150, WO07/75598,

WO08/36653, WO08/36642), indoximod, BMS-986205, or NLG-919 (WO09/73620, WO09/1156652, WO11/56652, WO12/142237).

In another aspect, the immuno-oncology agent is an OX40 agonist, such as an agonistic OX40 antibody. Suitable OX40 antibodies include, for example, MEDI-6383 or  
5 MEDI-6469.

In another aspect, the immuno-oncology agent is an OX40L antagonist, such as an antagonistic OX40 antibody. Suitable OX40L antagonists include, for example, RG-7888 (WO06/029879).

In another aspect, the immuno-oncology agent is a CD40 agonist, such as an  
10 agonistic CD40 antibody. In yet another embodiment, the immuno-oncology agent is a CD40 antagonist, such as an antagonistic CD40 antibody. Suitable CD40 antibodies include, for example, lucatumumab or dacetuzumab.

In another aspect, the immuno-oncology agent is a CD27 agonist, such as an agonistic CD27 antibody. Suitable CD27 antibodies include, for example, varlilumab.

15 In another aspect, the immuno-oncology agent is MGA271 (to B7H3) (WO11/109400).

The combination therapy is intended to embrace administration of these therapeutic agents in a sequential manner, that is, wherein each therapeutic agent is administered at a different time, as well as administration of these therapeutic agents, or  
20 at least two of the therapeutic agents, in a substantially simultaneous manner. Substantially simultaneous administration can be accomplished, for example, by administering to the subject a single dosage form having a fixed ratio of each therapeutic agent or in multiple, single dosage forms for each of the therapeutic agents. Sequential or substantially simultaneous administration of each therapeutic agent can be effected by  
25 any appropriate route including, but not limited to, oral routes, intravenous routes, intramuscular routes, and direct absorption through mucous membrane tissues. The therapeutic agents can be administered by the same route or by different routes. For example, a first therapeutic agent of the combination selected may be administered by intravenous injection while the other therapeutic agents of the combination may be  
30 administered orally. Alternatively, for example, all therapeutic agents may be administered orally or all therapeutic agents may be administered by intravenous injection. Combination therapy also can embrace the administration of the therapeutic

agents as described above in further combination with other biologically active ingredients and non-drug therapies (*e.g.*, surgery or radiation treatment.) Where the combination therapy further comprises a non-drug treatment, the non-drug treatment may be conducted at any suitable time so long as a beneficial effect from the co-action of the combination of the therapeutic agents and non-drug treatment is achieved. For example, 5 in appropriate cases, the beneficial effect is still achieved when the non-drug treatment is temporally removed from the administration of the therapeutic agents, perhaps by days or even weeks.

As used herein, the term "cell" is meant to refer to a cell that is *in vitro*, *ex vivo* or 10 *in vivo*. In some embodiments, an *ex vivo* cell can be part of a tissue sample excised from an organism such as a mammal. In some embodiments, an *in vitro* cell can be a cell in a cell culture. In some embodiments, an *in vivo* cell is a cell living in an organism such as a mammal.

As used herein, the term "contacting" refers to the bringing together of indicated 15 moieties in an *in vitro* system or an *in vivo* system. For example, "contacting" the DGK $\alpha$  and DGK $\zeta$  enzyme with a compound of Formula (I) includes the administration of a compound of the present invention to an individual or patient, such as a human, having DGK $\alpha$  and DGK $\zeta$ , as well as, for example, introducing a compound of Formula (I) into a sample containing a cellular or purified preparation containing DGK $\alpha$  and DGK $\zeta$  20 enzyme.

The term "DGK $\alpha$  and DGK $\zeta$  inhibitor" refers to an agent capable of inhibiting the activity of diacylglycerol kinase alpha and/or diacylglycerol kinase zeta (DGK $\alpha$  and DGK $\zeta$ ) in T cells resulting in T cell stimulation. The DGK $\alpha$  and DGK $\zeta$  inhibitor may be a reversible or irreversible DGK $\alpha$  and DGK $\zeta$  inhibitor. "A reversible DGK $\alpha$  and DGK $\zeta$  25 inhibitor" is a compound that reversibly inhibits DGK $\alpha$  and DGK $\zeta$  enzyme activity either at the catalytic site or at a non-catalytic site and "an irreversible DGK $\alpha$  and DGK $\zeta$  inhibitor" is a compound that irreversibly destroys DGK $\alpha$  and DGK $\zeta$  enzyme activity by forming a covalent bond with the enzyme.

Types of cancers that may be treated with the compound of Formula (I) include, 30 but are not limited to, brain cancers, skin cancers, bladder cancers, ovarian cancers, breast cancers, gastric cancers, pancreatic cancers, prostate cancers, colon cancers, blood

cancers, lung cancers and bone cancers. Examples of such cancer types include neuroblastoma, intestine carcinoma such as rectum carcinoma, colon carcinoma, familial adenomatous polyposis carcinoma and hereditary non-polyposis colorectal cancer, esophageal carcinoma, labial carcinoma, larynx carcinoma, hypopharynx carcinoma, tongue carcinoma, salivary gland carcinoma, gastric carcinoma, adenocarcinoma, medullary thyroid carcinoma, papillary thyroid carcinoma, renal carcinoma, kidney parenchymal carcinoma, ovarian carcinoma, cervix carcinoma, uterine corpus carcinoma, endometrium carcinoma, chorion carcinoma, pancreatic carcinoma, prostate carcinoma, testis carcinoma, breast carcinoma, urinary carcinoma, melanoma, brain tumors such as glioblastoma, astrocytoma, meningioma, medulloblastoma and peripheral neuroectodermal tumors, Hodgkin lymphoma, non-Hodgkin lymphoma, Burkitt lymphoma, acute lymphatic leukemia (ALL), chronic lymphatic leukemia (CLL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), adult T-cell leukemia lymphoma, diffuse large B-cell lymphoma (DLBCL), hepatocellular carcinoma, gall bladder carcinoma, bronchial carcinoma, small cell lung carcinoma, non-small cell lung carcinoma, multiple myeloma, basalioma, teratoma, retinoblastoma, choroid melanoma, seminoma, rhabdomyosarcoma, craniopharyngioma, osteosarcoma, chondrosarcoma, myosarcoma, liposarcoma, fibrosarcoma, Ewing sarcoma and plasmocytoma.

One or more additional pharmaceutical agents or treatment methods such as, for example, anti-viral agents, chemotherapeutics or other anti-cancer agents, immune enhancers, immunosuppressants, radiation, anti-tumor and anti-viral vaccines, cytokine therapy (*e.g.*, IL2 and GM-CSF), and/or tyrosine kinase inhibitors can be optionally used in combination with the compounds of Formula (I) for treatment of DGK $\alpha$  and DGK $\zeta$  associated diseases, disorders or conditions. The agents can be combined with the present compounds in a single dosage form, or the agents can be administered simultaneously or sequentially as separate dosage forms.

Suitable chemotherapeutic or other anti-cancer agents include, for example, alkylating agents (including, without limitation, nitrogen mustards, ethylenimine derivatives, alkyl sulfonates, nitrosoureas and triazines) such as uracil mustard, chlormethine, cyclophosphamide (CYTOXAN®), ifosfamide, melphalan, chlorambucil, pipobroman, triethylene-melamine, triethylenethiophosphoramine, busulfan, carmustine, lomustine, streptozocin, dacarbazine, and temozolomide.

In the treatment of melanoma, suitable agents for use in combination with the compounds of Formula (I) include: dacarbazine (DTIC), optionally, along with other chemotherapy drugs such as carmustine (BCNU) and cisplatin; the "Dartmouth regimen", which consists of DTIC, BCNU, cisplatin and tamoxifen; a combination of cisplatin, 5 vinblastine, and DTIC, temozolomide or YERVOY™. Compounds of Formula (I) may also be combined with immunotherapy drugs, including cytokines such as interferon alpha, interleukin 2, and tumor necrosis factor (TNF) in the treatment of melanoma.

Compounds of Formula (I) may also be used in combination with vaccine therapy in the treatment of melanoma. Antimelanoma vaccines are, in some ways, similar to the 10 anti-virus vaccines which are used to prevent diseases caused by viruses such as polio, measles, and mumps. Weakened melanoma cells or parts of melanoma cells called antigens may be injected into a patient to stimulate the body's immune system to destroy melanoma cells.

Melanomas that are confined to the arms or legs may also be treated with a 15 combination of agents including one or more compounds of Formula (I), using a hyperthermic isolated limb perfusion technique. This treatment protocol temporarily separates the circulation of the involved limb from the rest of the body and injects high doses of chemotherapy into the artery feeding the limb, thus providing high doses to the area of the tumor without exposing internal organs to these doses that might otherwise 20 cause severe side effects. Usually the fluid is warmed to 38.9 °C to 40 °C. Melphalan is the drug most often used in this chemotherapy procedure. This can be given with another agent called tumor necrosis factor (TNF).

Suitable chemotherapeutic or other anti-cancer agents include, for example, antimetabolites (including, without limitation, folic acid antagonists, pyrimidine analogs, 25 purine analogs and adenosine deaminase inhibitors) such as methotrexate, 5-fluorouracil, floxuridine, cytarabine, 6-mercaptopurine, 6-thioguanine, fludarabine phosphate, pentostatine, and gemcitabine.

Suitable chemotherapeutic or other anti-cancer agents further include, for example, certain natural products and their derivatives (for example, vinca alkaloids, 30 antitumor antibiotics, enzymes, lymphokines and epipodophyllotoxins) such as vinblastine, vincristine, vindesine, bleomycin, dactinomycin, daunorubicin, doxorubicin, epirubicin, idarubicin, ara-C, paclitaxel (Taxol), mithramycin, deoxyco-formycin,

mitomycin-C, L-asparaginase, interferons (especially IFN- $\alpha$ ), etoposide, and teniposide.

Other cytotoxic agents include navelbene, CPT-11, anastrozole, letrozole, capecitabine, reloxafine, and droloxafine.

Also suitable are cytotoxic agents such as epidophyllotoxin; an antineoplastic  
5 enzyme; a topoisomerase inhibitor; procarbazine; mitoxantrone; platinum coordination  
complexes such as cisplatin and carboplatin; biological response modifiers; growth  
inhibitors; antihormonal therapeutic agents; leucovorin; tegafur; and haematopoietic  
growth factors.

Other anti-cancer agent(s) include antibody therapeutics such as trastuzumab  
10 (HERCEPTIN®), antibodies to costimulatory molecules such as CTLA-4, 4-1BB and  
PD-1, or antibodies to cytokines (IL-10 or TGF- $\beta$ ).

Other anti-cancer agents also include those that block immune cell migration such  
as antagonists to chemokine receptors, including CCR2 and CCR4.

Other anti-cancer agents also include those that augment the immune system such  
15 as adjuvants or adoptive T cell transfer.

Anti-cancer vaccines include dendritic cells, synthetic peptides, DNA vaccines  
and recombinant viruses.

The pharmaceutical composition of the invention may optionally include at least  
one signal transduction inhibitor (STI). A "signal transduction inhibitor" is an agent that  
20 selectively inhibits one or more vital steps in signaling pathways, in the normal function  
of cancer cells, thereby leading to apoptosis. Suitable STIs include, but are not limited to:  
(i) bcr/abl kinase inhibitors such as, for example, STI 571 (GLEEVEC®); (ii) epidermal  
growth factor (EGF) receptor inhibitors such as, for example, kinase inhibitors  
(IRESSA®, SSI-774) and antibodies (Imclone: C225 [Goldstein et al., *Clin. Cancer Res.*,  
25 1:1311-1318 (1995)], and Abgenix: ABX-EGF); (iii) her-2/neu receptor inhibitors such as  
farnesyl transferase inhibitors (FTI) such as, for example, L-744,832 (Kohl et al., *Nat.  
Med.*, 1(8):792-797 (1995)); (iv) inhibitors of Akt family kinases or the Akt pathway,  
such as, for example, rapamycin (see, for example, Sekulic et al., *Cancer Res.*, 60:3504-  
3513 (2000)); (v) cell cycle kinase inhibitors such as, for example, flavopiridol and UCN-  
30 O1 (see, for example, Sausville, *Curr. Med. Chem. Anti-Canc. Agents*, 3:47-56 (2003));  
and (vi) phosphatidyl inositol kinase inhibitors such as, for example, LY294002 (see, for  
example, Vlahos et al., *J. Biol. Chem.*, 269:5241-5248 (1994)). Alternatively, at least one

STI and at least one compound of Formula (I) may be in separate pharmaceutical compositions. In a specific embodiment of the present invention, at least one compound of Formula (I) and at least one STI may be administered to the patient concurrently or sequentially. In other words, at least one compound of Formula (I) may be administered first, at least one STI may be administered first, or at least one compound of Formula (I) and at least one STI may be administered at the same time. Additionally, when more than one compound of Formula (I) and/or STI is used, the compounds may be administered in any order.

The present invention further provides a pharmaceutical composition for the treatment of a chronic viral infection in a patient comprising at least one compound of Formula (I), optionally, at least one chemotherapeutic drug, and, optionally, at least one antiviral agent, in a pharmaceutically acceptable carrier.

Also provided is a method for treating a chronic viral infection in a patient by administering an effective amount of the above pharmaceutical composition.

In a specific embodiment of the present invention, at least one compound of Formula (I) and at least one chemotherapeutic agent are administered to the patient concurrently or sequentially. In other words, at least one compound of Formula (I) may be administered first, at least one chemotherapeutic agent may be administered first, or at least one compound of Formula (I) and the at least one STI may be administered at the same time. Additionally, when more than one compound of Formula (I) and/or chemotherapeutic agent is used, the compounds may be administered in any order. Similarly, any antiviral agent or STI may also be administered at any point in comparison to the administration of the compound of Formula (I).

Chronic viral infections that may be treated using the present combinatorial treatment include, but are not limited to, diseases caused by: hepatitis C virus (HCV), human papilloma virus (HPV), cytomegalovirus (CMV), herpes simplex virus (HSV), Epstein-Barr virus (EBV), varicella zoster virus, coxsackie virus, human immunodeficiency virus (HIV). Notably, parasitic infections (*e.g.*, malaria) may also be treated by the above methods wherein compounds known to treat the parasitic conditions are optionally added in place of the antiviral agents.

Suitable antiviral agents contemplated for use in combination with the compound of Formula (I) can comprise nucleoside and nucleotide reverse transcriptase inhibitors

(NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors and other antiviral drugs.

Examples of suitable NRTIs include zidovudine (AZT); didanosine (ddl); zalcitabine (ddC); stavudine (d4T); lamivudine (3TC); abacavir (1592U89); adefovir dipivoxil [bis(POM)-PMEA]; lobucavir; BCH-I0652; emtricitabine [(-)-FTC]; beta-L-FD4 (also called beta-L-D4C and named beta-L-2',3'-dideoxy-5-fluoro-cytidene); DAPD, ((-)-beta-D-2,6-diamino-purine dioxolane); and lodenosine (FddA). Typical suitable NNRTIs include nevirapine (BI-RG-587); delaviradine (BHAP, U-90152); efavirenz (DMP-266); PNU-142721; AG-1549; MKC-442 (1-(ethoxy-methyl)-5-(1-methylethyl)-6-(phenylmethyl)-(2,4(1H,3H)-pyrimidinedione); and (+)-calanolide A (NSC-675451) and B. Typical suitable protease inhibitors include saquinavir (Ro 31-8959); ritonavir (ABT-538); indinavir (MK-639); nelfnavir (AG-1343); amprenavir (141W94); lasinavir; DMP-450; BMS-2322623; ABT-378; and AG-1549. Other antiviral agents include hydroxyurea, ribavirin, IL-2, IL-12, pentafuside and Yissum Project No.11607.

The present invention also includes pharmaceutical kits useful, for example, in the treatment or prevention of DGK $\alpha$  and DGK $\zeta$  -associated diseases or disorders, and other diseases referred to herein which include one or more containers containing a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula (I). Such kits can further include, if desired, one or more of various conventional pharmaceutical kit components, such as, for example, containers with one or more pharmaceutically acceptable carriers, additional containers, as will be readily apparent to those skilled in the art. Instructions, either as inserts or as labels, indicating quantities of the components to be administered, guidelines for administration, and/or guidelines for mixing the components, can also be included in the kit.

The combination therapy is intended to embrace administration of these therapeutic agents in a sequential manner, that is, wherein each therapeutic agent is administered at a different time, as well as administration of these therapeutic agents, or at least two of the therapeutic agents, in a substantially simultaneous manner. Substantially simultaneous administration can be accomplished, for example, by administering to the subject a single dosage form having a fixed ratio of each therapeutic agent or in multiple, single dosage forms for each of the therapeutic agents. Sequential or substantially simultaneous administration of each therapeutic agent can be effected by

any appropriate route including, but not limited to, oral routes, intravenous routes, intramuscular routes, and direct absorption through mucous membrane tissues. The therapeutic agents can be administered by the same route or by different routes. For example, a first therapeutic agent of the combination selected may be administered by intravenous injection while the other therapeutic agents of the combination may be administered orally. Alternatively, for example, all therapeutic agents may be administered orally or all therapeutic agents may be administered by intravenous injection. Combination therapy also can embrace the administration of the therapeutic agents as described above in further combination with other biologically active ingredients and non-drug therapies (*e.g.*, surgery or radiation treatment). Where the combination therapy further comprises a non-drug treatment, the non-drug treatment may be conducted at any suitable time so long as a beneficial effect from the co-action of the combination of the therapeutic agents and non-drug treatment is achieved. For example, in appropriate cases, the beneficial effect is still achieved when the non-drug treatment is temporally removed from the administration of the therapeutic agents, perhaps by days or even weeks.

The invention also provides pharmaceutically acceptable compositions which comprise a therapeutically effective amount of one or more of the compounds of Formula (I), formulated together with one or more pharmaceutically acceptable carriers (additives) and/or diluents, and optionally, one or more additional therapeutic agents described above.

The compounds of this invention can be administered for any of the uses described herein by any suitable means, for example, orally, such as tablets, capsules (each of which includes sustained release or timed release formulations), pills, powders, granules, elixirs, tinctures, suspensions (including nanosuspensions, microsuspensions, spray-dried dispersions), syrups, and emulsions; sublingually; buccally; parenterally, such as by subcutaneous, intravenous, intramuscular, or intrasternal injection, or infusion techniques (*e.g.*, as sterile injectable aqueous or non-aqueous solutions or suspensions); nasally, including administration to the nasal membranes, such as by inhalation spray; topically, such as in the form of a cream or ointment; or rectally such as in the form of suppositories. They can be administered alone, but generally will be administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and

standard pharmaceutical practice.

The phrase "pharmaceutically acceptable carrier" as used herein means a pharmaceutically acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, manufacturing aid (e.g., lubricant, talc magnesium, calcium or zinc stearate, or steric acid), or solvent encapsulating material, involved in carrying or transporting the subject compound from one organ, or portion of the body, to another organ, or portion of the body. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation, including, *i.e.*, adjuvant, excipient or vehicle, such as diluents, preserving agents, fillers, flow regulating agents, disintegrating agents, wetting agents, emulsifying agents, suspending agents, sweetening agents, flavoring agents, perfuming agents, antibacterial agents, antifungal agents, lubricating agents and dispensing agents, depending on the nature of the mode of administration and dosage forms; and not injurious to the patient.

The term "pharmaceutical composition" means a composition comprising a compound of the invention in combination with at least one additional pharmaceutically acceptable carrier.

Pharmaceutically acceptable carriers are formulated according to a number of factors well within the purview of those of ordinary skill in the art. These include, without limitation: the type and nature of the active agent being formulated; the subject to which the agent-containing composition is to be administered; the intended route of administration of the composition; and the therapeutic indication being targeted. Pharmaceutically acceptable carriers include both aqueous and non-aqueous liquid media, as well as a variety of solid and semi-solid dosage forms. Such carriers can include a number of different ingredients and additives in addition to the active agent, such additional ingredients being included in the formulation for a variety of reasons, *e.g.*, stabilization of the active agent, binders, etc., well known to those of ordinary skill in the art. Descriptions of suitable pharmaceutically acceptable carriers, and factors involved in their selection, are found in a variety of readily available sources such as, for example, Allen, L. V. Jr. *et al.* *Remington: The Science and Practice of Pharmacy (2 Volumes)*, 22nd Edition (2012), Pharmaceutical Press.

The dosage regimen for the compounds of the present invention will, of course, vary depending upon known factors, such as the pharmacodynamic characteristics of the

particular agent and its mode and route of administration; the species, age, sex, health, medical condition, and weight of the recipient; the nature and extent of the symptoms; the kind of concurrent treatment; the frequency of treatment; the route of administration, the renal and hepatic function of the patient, and the effect desired.

5           By way of general guidance, the daily oral dosage of each active ingredient, when used for the indicated effects, will range between about 0.001 to about 5000 mg per day, preferably between about 0.01 to about 1000 mg per day, and most preferably between about 0.1 to about 250 mg per day. Intravenously, the most preferred doses will range from about 0.01 to about 10 mg/kg/minute during a constant rate infusion. Compounds of  
10 this invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three, or four times daily.

The compounds are typically administered in admixture with suitable pharmaceutical diluents, excipients, or carriers (collectively referred to herein as pharmaceutical carriers) suitably selected with respect to the intended form of  
15 administration, *e.g.*, oral tablets, capsules, elixirs, and syrups, and consistent with conventional pharmaceutical practices.

Dosage forms (pharmaceutical compositions) suitable for administration may contain from about 1 milligram to about 2000 milligrams of active ingredient per dosage unit. In these pharmaceutical compositions the active ingredient will ordinarily be  
20 present in an amount of about 0.1-95% by weight based on the total weight of the composition.

A typical capsule for oral administration contains at least one of the compounds of the present invention (250 mg), lactose (75 mg), and magnesium stearate (15 mg). The mixture is passed through a 60 mesh sieve and packed into a No. L gelatin capsule.

25           A typical injectable preparation is produced by aseptically placing at least one of the compounds of the present invention (250 mg) into a vial, aseptically freeze-drying and sealing. For use, the contents of the vial are mixed with 2 mL of physiological saline, to produce an injectable preparation.

The present invention includes within its scope pharmaceutical compositions  
30 comprising, as an active ingredient, a therapeutically effective amount of at least one of the compounds of the present invention, alone or in combination with a pharmaceutical carrier. Optionally, compounds of the present invention can be used alone, in

combination with other compounds of the invention, or in combination with one or more other therapeutic agent(s), *e.g.*, an anticancer agent or other pharmaceutically active material.

Regardless of the route of administration selected, the compounds of the present invention, which may be used in a suitable hydrated form, and/or the pharmaceutical compositions of the present invention, are formulated into pharmaceutically acceptable dosage forms by conventional methods known to those of skill in the art.

Actual dosage levels of the active ingredients in the pharmaceutical compositions of this invention may be varied so as to obtain an amount of the active ingredient which is effective to achieve the therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient.

The selected dosage level will depend upon a variety of factors including the activity of the particular compound of the present invention employed, or the ester, salt or amide thereof, the route of administration, the time of administration, the rate of excretion or metabolism of the particular compound being employed, the rate and extent of absorption, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular compound employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.

A physician or veterinarian having ordinary skill in the art can readily determine and prescribe the effective amount of the pharmaceutical composition required. For example, the physician or veterinarian could start doses of the compounds of the invention employed in the pharmaceutical composition at levels lower than that required in order to achieve the therapeutic effect and gradually increase the dosage until the effect is achieved.

In general, a suitable daily dose of a compound of the invention will be that amount of the compound which is the lowest dose effective to produce a therapeutic effect. Such an effective dose will generally depend upon the factors described above. Generally, oral, intravenous, intracerebroventricular and subcutaneous doses of the compounds of this invention for a patient will range from about 0.01 to about 50 mg per kilogram of body weight per day.

If desired, the effective daily dose of the active compound may be administered as

two, three, four, five, six or more sub-doses administered separately at appropriate intervals throughout the day, optionally, in unit dosage forms. In certain aspects of the invention, dosing is one administration per day.

While it is possible for a compound of the present invention to be administered  
5 alone, it is preferable to administer the compound as a pharmaceutical formulation (composition).

The above other therapeutic agents, when employed in combination with the compounds of the present invention, may be used, for example, in those amounts indicated in the Physicians' Desk Reference (PDR) or as otherwise determined by one of  
10 ordinary skill in the art. In the methods of the present invention, such other therapeutic agent(s) may be administered prior to, simultaneously with, or following the administration of the inventive compounds.

#### METHODS OF PREPARATION

15 The compounds of the present invention may be synthesized by many methods available to those skilled in the art of organic chemistry. General synthetic schemes for preparing compounds of the present invention are described below. These schemes are illustrative and are not meant to limit the possible techniques one skilled in the art may use to prepare the compounds disclosed herein. Different methods to prepare the  
20 compounds of the present invention will be evident to those skilled in the art. Examples of compounds of the present invention prepared by methods described in the general schemes are given in the Examples section set out hereinafter. Preparation of homochiral examples may be carried out by techniques known to one skilled in the art. For example, homochiral compounds may be prepared by separation of racemic products or  
25 diastereomers by chiral phase preparative HPLC. Alternatively, the example compounds may be prepared by methods known to give enantiomerically or diastereomerically enriched products.

The reactions and techniques described in this section are performed in solvents appropriate to the reagents and materials employed and are suitable for the  
30 transformations being effected. Also, in the description of the synthetic methods given below, it is to be understood that all proposed reaction conditions, including choice of solvent, reaction atmosphere, reaction temperature, duration of the experiment and work

up procedures, are chosen to be the conditions standard for that reaction, which should be readily recognized by one skilled in the art. It is understood by one skilled in the art of organic synthesis that the functionality present on various portions of the molecule must be compatible with the reagents and reactions proposed. Such restrictions to the

5 substituents that are compatible with the reaction conditions will be readily apparent to one skilled in the art, with alternatives required when incompatible substituents are present. This will sometimes require a judgment to modify the order of the synthetic steps or to select one particular process scheme over another in order to obtain a compound of the invention. It will also be recognized that another major consideration in

10 the planning of any synthetic route in this field is the judicious choice of a protecting group used for protection of reactive functional groups present in the compounds described in this invention. An authoritative account describing the many alternatives to the trained practitioner is Wuts and Greene, *Greene's Protective Groups in Organic Synthesis*, Fourth Edition, Wiley and Sons (2007).

15

#### EXAMPLES

The following examples illustrate the particular and preferred embodiments of the present invention and do not limit the scope of the present invention. Chemical abbreviations and symbols as well as scientific abbreviations and symbols have their

20 usual and customary meanings unless otherwise specified. Additional abbreviations employed in the Examples and elsewhere in this application are defined above. Common intermediates are generally useful for the preparation of more than one Example and are identified sequentially (e.g., Intermediate 1, Intermediate 2, etc.) and are abbreviated as Int. 1 or I1, Int. 2 or I2, etc. Compounds of the Examples are identified by the example

25 and step in which they were prepared (e.g., "1-A" denotes the Example 1, step A), or by the example only where the compound is the title compound of the example (for example, "1" denotes the title compound of Example 1). In some instances alternate preparations of intermediates or examples are described. Frequently chemists skilled in the art of synthesis may devise alternative preparations which may be desirable based on one or

30 more considerations such as shorter reaction time, less expensive starting materials, ease of operation or isolation, improved yield, amenable to catalysis, avoidance of toxic reagents, accessibility of specialized instrumentation, and decreased number of linear

steps, etc. The intent of describing alternative preparations is to further enable the preparation of the examples of this invention. In some instances some functional groups in the outlined examples and claims may be replaced by well-known bioisosteric replacements known in the art, for example, replacement of a carboxylic acid group with a tetrazole or a phosphate moiety. <sup>1</sup>H NMR data collected in deuterated dimethyl sulfoxide used water suppression in the data processing. The reported spectra are uncorrected for the effects of water suppression. Protons adjacent to the water suppression frequency of 3.35 ppm exhibit diminished signal intensity.

10


## ABBREVIATIONS

Ac	acetyl
anhyd.	anhydrous
aq.	aqueous
Boc	<i>tert</i> -butoxycarbonyl
15 BOP	benzotriazol-1-yloxytris-(dimethylamino)-phosphonium hexafluorophosphate
Bu	butyl
CDI	carbonyldiimidazole
DCM	dichloromethane
20 DEA	diethylamine
DIEA or DIPEA	diisopropylethylamine
DMF	dimethylformamide
DMSO	dimethyl sulfoxide
dppf	1,1'-bis(diphenylphosphino)ferrocene
25 Et	ethyl
EtOAc	ethyl acetate
EtOH	ethanol
h, hours or hrs	hour(s)
HCl	hydrochloric acid
30 HPLC	high pressure liquid chromatography
LC	liquid chromatography
LCMS	liquid chromatography- mass spectrometry

	M	molar
	mM	millimolar
	Me	methyl
	MeOH	methanol
5	Mesyl-Cl	methanesulfonyl chloride
	MHz	megahertz
	mins	minute(s)
	M <sup>+1</sup>	(M+H) <sup>+</sup>
	MS	mass spectrometry
10	n or N	normal
	NH <sub>4</sub> OAc	ammonium acetate
	nM	nanomolar
	NMP	<i>N</i> -methylpyrrolidinone
	Pd <sub>2</sub> (dba) <sub>3</sub>	tris-(dibenzylideneacetone)dipalladium
15	pet ether	petroleum ether
	Ph	phenyl
	POCl <sub>3</sub>	phosphorous oxychloride
	rt or Ret time	retention time
	sat.	saturated
20	TEA	triethylamine
	TFA	trifluoroacetic acid
	THF	tetrahydrofuran

## INTERMEDIATE 1

25 N-(4-bromo-2-cyanophenyl)-2,2,2-trifluoroacetamide




To a solution of 2-amino-5-bromobenzonitrile (10 g, 50.8 mmol) in THF (200 mL) at 0 °C were added triethylamine (10.61 mL, 76 mmol) and 2,2,2-trifluoroacetic anhydride (7.82 mL, 55.8 mmol) dropwise. The reaction mixture was stirred at room

temperature for 3 h. The reaction was quenched with ice water. The reaction mixture was extracted with ethyl acetate (2x100 mL). The combined organic layer was washed with water, brine and dried over sodium sulfate. The solvent was evaporated under reduced pressure to afford crude product, which was purified by silica gel column chromatography using 24 g flash column and 20% EtOAc in petroleum ether. The fractions were concentrated under reduced pressure to afford purified N-(4-bromo-2-cyanophenyl)-2,2,2-trifluoroacetamide (8 g, 51.1 % yield). LCMS:  $m/z = 292.9$  (M+H)<sup>-</sup>; rt 1.19 min. (LCMS Method: Column: Aquity UPLC BEH C18 (3.0 x 50 mm) 1.7 μm Mobile phase A: 10 mM NH<sub>4</sub>OAc: ACN (95:5) Mobile phase B: 10 mM NH<sub>4</sub>OAc: Acetonitrile (5:95) Description: Method: %B: 0 min-20: 2 min-100: 2.3 min-100, Flow: 0.7 ml/min; Detection: UV at 220 nm). <sup>1</sup>H NMR (400MHz, CHLOROFORM-d) δ (ppm) 8.30-8.28 (m, 2H), 7.85-7.80 (m, 2H).

## INTERMEDIATE 2


15 N-(4-bromo-2-cyanophenyl)-2,2,2-trifluoro-N-methylacetamide



To a solution of N-(4-bromo-2-cyanophenyl)-2,2,2-trifluoroacetamide (8 g, 27.3 mmol) in DMF (25 mL) at room temperature were added potassium carbonate (9.43 g, 68.2 mmol), followed by methyl iodide (8.54 mL, 136 mmol). The reaction mixture was stirred at room temperature for 16 h. The reaction mixture was quenched with water and extracted with ethyl acetate (2 x 100 mL). The combined organic layer was washed with water, brine and dried over sodium sulfate. The solvent was evaporated under reduced pressure to afford N-(4-bromo-2-cyanophenyl)-2,2,2-trifluoro-N-methylacetamide (6 g, 71.6 % yield). LCMS:  $m/z = 213.0$  (M-COCF<sub>3</sub>+H)<sup>+</sup>; rt 1.57 min. (Column: Aquity UPLC BEH C18 (3.0 x 50 mm) 1.7 μm phase A: 10 mM NH<sub>4</sub>OAc: ACN (95:5) M.phase B: 10mM NH<sub>4</sub>OAc: ACN (5:95) Description: Method:%B: 0 min-20:2 min-100:2.3 min-100, Flow: 0.7 mL/min.

## INTERMEDIATE 3


## 5-Bromo-2-(methylamino)benzamide



To a solution of N-(4-bromo-2-cyanophenyl)-2,2,2-trifluoro-N-methylacetamide (8 g, 26.1 mmol) in DMSO (80 mL)/water (40 ml) at 0 °C was added K<sub>2</sub>CO<sub>3</sub> (7.2 g, 52.1 mmol), followed by hydrogen peroxide (37%, 10.73 mL, 105 mmol) drop wise over a period of 10 minutes. The reaction mixture was stirred at room temperature for 2 hours and thereafter quenched with ice water. The solids were separated by filtration and washed with water and dried under reduced pressure to afford 5-bromo-2-(methylamino) benzamide (4 g, 59.0 % yield). LCMS: *m/z* = 229.1 (M+H)<sup>+</sup>; rt 1.14 min. Mobile phase A: 10 mM NH<sub>4</sub>OAc:ACN (95:5) Mobile phase B: 10 mM NH<sub>4</sub>OAc:ACN (5:95) Method: %B: 0 min-20%:1.1 min -90%:1.7 min-90% Column Name: Aquity UPLC BEH 18 (3.0 x 50 mm) 1.7 μm, Flow: 0.7 mL/min

## INTERMEDIATE 4

6-bromo-1-methylquinazoline-2,4(1H,3H)-dione




To a solution of 5-bromo-2-(methylamino)benzamide (4 g, 17.46 mmol) in *N,N*-dimethylformamide (40 mL) was added NaH (1.379 g, 34.9 mmol, 60 % w/w) at 0 °C. The reaction mixture was stirred for 1 hour at room temperature. A solution of CDI (4.25 g, 26.2 mmol) in dimethylformamide (5 mL) was added and the reaction mixture was heated at 70 °C for 2 h. The reaction mixture was cooled to room temperature. The solid product was separated by filtration, washed with water and dried under reduced pressure to afford 6-bromo-1-methylquinazoline-2,4(1H,3H)-dione (3 g, 67.4 % yield). LCMS: *m/z* = 255.0 (M+H); retention time 0.91 min. (Column: Aquity UPLC BEH C18 (3.0 x 50 mm) 1.7 μm M. phase A: 10 mM NH<sub>4</sub>OAc:ACN (95:5) M.phaseB: 10 mM NH<sub>4</sub>OAc:ACN (5:95) Method: %B: 0 min-20:2 min-100:2.3 min-100, Flow: 0.7

mL/min).  $^1\text{H}$  NMR (DMSO- $d_6$ , 400 MHz):  $\delta$  (ppm) 11.70 (br s, 1H), 8.04 (d,  $J=2.4$  Hz, 1H), 7.91 (dd,  $J=8.8, 2.4$  Hz, 1H), 7.40 (d,  $J=9.0$  Hz, 1H), 3.43 (s, 3H).

## INTERMEDIATE 5

5 6-bromo-4-chloro-1-methylquinazolin-2(1H)-one




To a suspension of 6-bromo-1-methylquinazoline-2,4(1H,3H)-dione (1 g, 3.92 mmol) in dry toluene (30 mL) were added DIPEA (1.712 mL, 9.80 mmol) and POCl<sub>3</sub> (1.827 mL, 19.60 mmol) at room temperature. The reaction mixture was heated at 110 °C  
 10 for 16 h. The reaction mixture was cooled to room temperature and the solvent was removed under reduced pressure to afford 6-bromo-4-chloro-1-methylquinazolin-2(1H)-one (1 g, 41.0 % yield). LCMS:  $m/z = 273.0$  (M+H)<sup>+</sup>; rt 1.71 min. (LCMS Method: Column-Kinetex XB-C18 (75 X 3 mm-2.6  $\mu\text{m}$ ) M.phase A: 10 mM NH<sub>4</sub>COOH in water:ACN (98:2) M.phase B: 10 mM NH<sub>4</sub>COOH in water:ACN (2:98).

15

## INTERMEDIATE 6

tert-butyl (2R,5S)-4-(6-bromo-1-methyl-2-oxo-1,2-dihydroquinazolin-4-yl)-2-ethyl-5-methylpiperazine-1-carboxylate




20 To a stirred solution of tert-butyl (2R,5S)-2-ethyl-5-methylpiperazine-1-carboxylate (CAS# 2165403-17-6) (1 g, 3.48 mmol) in acetonitrile (20 mL) was added DIPEA (6.08 mL, 34.8 mmol). The reaction mixture was stirred at room temperature for 15 min. To the reaction mixture was added 6-bromo-4-chloro-1-methylquinazolin-2(1H)-one (0.952 g, 3.48 mmol). The reaction mixture was heated at 85 °C for 6 h. The

reaction mixture was cooled to room temperature and concentrated under reduced pressure to obtain crude product, which was purified *via* silica gel column chromatography (60-70% EtOAc/petroleum ether; 40 g column) to afford tert-butyl (2R,5S)-4-(6-bromo-1-methyl-2-oxo-1,2-dihydroquinazolin-4-yl)-2-ethyl-5-methylpiperazine-1-carboxylate (0.8 g, 33.6 %). LCMS:  $m/z = 467.2$  (M+H); rt 1.74 min. LCMS Method: Column: Waters Acquity UPLC BEH C18 (2.1 x 50 mm) 1.7  $\mu\text{m}$ , Mobile phase A: 10 mM ammonium acetate:acetonitrile (95:5); Mobile phase B: 10 mM ammonium acetate:acetonitrile (5:95), Gradient = 20 % B over 1.1 minute, then a 2.2 minute hold at 100 % B; Temperature: 50 °C; Flow rate: 0.7 mL/min; Detection: UV at 110 nm).

## INTERMEDIATE 7

tert-butyl (2R,5S)-4-(6-cyano-1-methyl-2-oxo-1,2-dihydroquinazolin-4-yl)-2-ethyl-5-methylpiperazine-1-carboxylate




To a stirred solution of tert-butyl (2R,5S)-4-(6-bromo-1-methyl-2-oxo-1,2-dihydroquinazolin-4-yl)-2-ethyl-5-methylpiperazine-1-carboxylate (0.3 g, 0.645 mmol) in NMP (2 mL) were added zinc cyanide (0.151 g, 1.289 mmol) and zinc (0.042 g, 0.645 mmol). The reaction mixture was degassed for 5 min, followed by addition of  $\text{Pd}_2(\text{dba})_3$  (0.059 g, 0.064 mmol), dppf (0.071 g, 0.129 mmol) and heated at 90 °C overnight. The reaction mixture was cooled to room temperature, diluted with ethyl acetate and filtered through a Celite pad. The filtrate was washed with water, brine and the organic layer was dried over anhydrous  $\text{Na}_2\text{SO}_4$ , filtered and evaporated under reduced pressure to obtain the crude compound. The crude compound was purified *via* silica gel chromatography (70-80% EtOAc/petroleum ether; 24 g column) to afford the tert-butyl (2R,5S)-4-(6-cyano-1-methyl-2-oxo-1,2-dihydroquinazolin-4-yl)-2-ethyl-5-methylpiperazine-1-carboxylate (0.23g, 63.3 % yield) LCMS:  $m/z = 412.3$  (M+H)<sup>+</sup>; rt 0.65min. LCMS

Method: Column: Waters Acquity UPLC BEH C18 (2.1 x 50 mm) 1.7  $\mu$ m, Mobile phase A: 10 mM ammonium acetate:acetonitrile (95:5); Mobile phase B: 10 mM ammonium acetate:acetonitrile (5:95), Gradient = 20 % B over 1.1 minute, then a 2.2 minute hold at 100 % B; Temperature: 50  $^{\circ}$ C; Flow rate: 0.7 mL/min; Detection: UV at 110 nm).

5

## INTERMEDIATE 8

4-((2S,5R)-5-ethyl-2-methylpiperazin-1-yl)-1-methyl-2-oxo-1,2-dihydroquinazoline-6-carbonitrile




10 To a stirred solution of tert-butyl (2R,5S)-4-(6-cyano-1-methyl-2-oxo-1,2-dihydroquinazolin-4-yl)-2-ethyl-5-methylpiperazine-1-carboxylate (0.1 g, 0.243 mmol) in dry DCM (5 mL) was added TFA (0.281 mL, 3.65 mmol) at room temperature. The reaction mixture was stirred for 3 h. The solvent was removed under reduced pressure to afford 4-((2S,5R)-5-ethyl-2-methylpiperazin-1-yl)-1-methyl-2-oxo-1,2-

15 dihydroquinazoline-6-carbonitrile, TFA (0.1 g, 0.202 mmol, 83 % yield). LCMS:  $m/z$  = 312.2 (M+H)<sup>+</sup>; rt 0.68 min. LCMS Method: Column: Waters Acquity UPLC BEH C18 (2.1 x 50 mm) 1.7  $\mu$ m, Mobile phase A: 10 mM ammonium acetate:acetonitrile (95:5); Mobile phase B: 10 mM ammonium acetate: acetonitrile (5:95), Gradient = 20 % B over 1.1 minute, then a 2.2 minute hold at 100 % B; Temperature: 50  $^{\circ}$ C; Flow rate: 0.7

20 mL/min; Detection: UV at 110 nm).

## EXAMPLES 1 AND 2

4-((2S,5R)-5-ethyl-2-methyl-4-(1-(4-(trifluoromethyl)phenyl)ethyl)piperazin-1-yl)-1-methyl-2-oxo-1,2-dihydroquinazoline-6-carbonitrile



To a solution of 4-((2S,5R)-5-ethyl-2-methylpiperazin-1-yl)-1-methyl-2-oxo-1,2-dihydroquinazoline-6-carbonitrile, TFA (0.2 g, 0.47 mmol) in acetonitrile (5 mL) at room temperature was added DIPEA (0.246 mL, 1.410 mmol). The reaction mixture was heated at 85 °C for 15 mins. Next, 1-(1-chloroethyl)-4-(trifluoromethyl)benzene (0.196 g, 0.940 mmol) (CAS- 85289-90-3) and sodium iodide (0.07g, 0.47 mmol) were added to the reaction mixture. The reaction mixture was heated at 85 °C for 16 h. The reaction mixture was cooled to room temperature and the solvent was removed under reduced pressure. The residue was dissolved in ethyl acetate (100 mL). The organic layer was washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure to yield the crude product as a diastereomer mixture, which was purified by preparative HPLC [HPLC Method: Column: EVO C18 (20 X 250 mm), 5 μm Mobile Phase A- 10 mM ammonium bicarbonate B: ACN/MeOH Flow: 20 mL, to yield Peak 1 (Example 1) and Peak 2 (Example 2).

Fraction 1 (Peak 1) was concentrated under reduced pressure and the residue was diluted with (EtOH/H<sub>2</sub>O, 1:5) and lyophilized to yield Example 1 (6 mg, 2.6 % yield); LCMS: *m/z* = 484.3 (M+H)<sup>+</sup>; rt 2.249 min; (LCMS method: Column: XBridge BEH XP C18 (50 x2.1 mm), 2.5 μm; Mobile phase A: 95 % water: 5% acetonitrile; 10 mM ammonium acetate; Mobile phase B: 5% Water: 95% acetonitrile; 10 mM ammonium acetate; Flow: 1.1 mL/min; Temp: 50 °C; Time (min): 0-3; %B: 0-100 %). <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>) δ 8.16 (d, J=1.7 Hz, 1H), 8.04 (dd, J=8.8, 1.7 Hz, 1H), 7.76-7.68 (m, 2H), 7.62 (d, J=8.1 Hz, 2H), 7.53 (d, J=8.8Hz, 1H), 4.77-4.66 (m, 1H), 3.97-3.88 (m, 1H), 3.88-3.79 (m, 1H), 3.64-3.57 (m, 1H), 3.45 (s, 3H), 2.91-2.84 (m, 1H), 2.82-2.74 (m, 1H), 2.37-2.32 (m, 1H), 1.44 (d, J=6.6 Hz, 3H), 1.35-1.24 (m, 5H), 0.48 (t, J=7.5 Hz, 3H)

Fraction 2 (Peak 2) was concentrated under reduced pressure and the residue was

diluted with (EtOH/H<sub>2</sub>O:1:5) and lyophilized to yield Example 2 (0.07 g, 0.144 mmol, 10.27 % yield); LCMS: *m/z* = 484.3 (M+H); rt 2.27 min; (LCMS Method: Column: XBridge BEH XP C18 (50 x 2.1 mm), 2.5 μm; Mobile phase A: 95% water: 5% acetonitrile; 10 mM ammonium acetate; Mobile phase B: 5% water: 95% acetonitrile; 10 mM ammonium acetate; Flow: 1.1 mL/min; Temp: 50 °C; Time (min): 0-3; %B: 0-100  
5 <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>) δ ppm 8.15 (d, J=1.7 Hz, 1H), 8.05 (dd, J=8.8, 1.7 Hz, 1H), 7.76-7.66 (m, 2H), 7.66-7.57 (m, 2H), 7.54 (d, J=9.0 Hz, 1H), 4.57-4.47 (m, 1H), 4.16 (br d, J=13.4 Hz, 1H), 3.79-3.67 (m, 2H), 3.45 (s, 3H), 3.11-3.02 (m, 1H), 2.74-2.67 (m, 1H), 2.12 (dd, J=12.0, 2.0 Hz, 1H), 1.54-1.41 (m, 2H), 1.26 (dd, J=6.4, 3.4 Hz, 6H),  
10 0.78 (t, J=7.5 Hz, 3H).

### BIOLOGICAL ASSAYS

The pharmacological properties of the compounds of this invention may be confirmed by a number of biological assays. The exemplified biological assays, which  
15 follow, have been carried out with compounds of the invention.

#### Assay 1: In vitro DGK Inhibition Assays – Method A

The DGK $\alpha$  and DGK $\zeta$  reactions were performed using either extruded liposome (DGK $\alpha$  and DGK $\zeta$  LIPGLO assays) or detergent/lipid micelle substrate (DGK $\alpha$  and  
20 DGK $\zeta$  assays). The reactions were carried out in 50 mM MOPS pH 7.5, 100 mM NaCl, 10 mM MgCl<sub>2</sub>, 1 μM CaCl<sub>2</sub>, and 1 mM DTT (assay buffer). The reactions using a detergent/lipid micelle substrate also contained 50 mM octyl B-D-glucopyranoside. The lipid substrate concentrations were 11 mM PS and 1 mM DAG for the detergent/lipid micelle reactions. The lipid substrate concentrations were 2 mM PS, 0.25 mM DAG, and  
25 2.75 mM PC for the extruded liposome reactions. The reactions were carried out in 150 μM ATP. The enzyme concentrations for the DGK $\alpha$  and DGK $\zeta$  were 5 nM

The compound inhibition studies were carried out as follows: 50 nL droplets of each test compound (top concentration 10 mM with 11 point, 3-fold dilution series for each compound) solubilized in DMSO were transferred to wells of a white 1536 well  
30 plate (Corning 3725). A 5 mL enzyme/substrate solution at 2x final reaction concentration was prepared by combining 2.5 mL 4x enzyme solution (20 nM DGK $\alpha$  or

DGK $\zeta$  (prepared as described below) in assay buffer) and 2.5 mL of either 4x liposome or 4x detergent/lipid micelle solution (compositions described below) and incubated at room temperature for 10 minutes. Next, 1  $\mu$ L 2x enzyme/substrate solution was added to wells containing the test compound and reactions were initiated with the addition of 1  $\mu$ L 300  
5  $\mu$ M ATP. The reactions were allowed to proceed for 1 hr, after which 2  $\mu$ L Glo Reagent (Promega V9101) was added and incubated for 40 minutes. Next, 4  $\mu$ L Kinase Detection Reagent was added and incubated for 30 minutes. Luminescence was recorded using an EnVision microplate reader. The percent inhibition was calculated from the ATP conversion generated by no enzyme control reactions for 100 % inhibition and vehicle-  
10 only reactions for 0 % inhibition. The compounds were evaluated at 11 concentrations to determine IC<sub>50</sub>.

#### 4x Detergent/lipid Micelle Preparation

The detergent/lipid micelle was prepared by combining 15 g phosphatidylserine  
15 (Avanti 840035P) and 1 g diacylglycerol (800811O) and dissolving into 150 mL chloroform in a 2 L round bottom flask. Chloroform was removed under high vacuum by rotary evaporation. The resulting colorless, tacky oil was resuspended in 400 mL 50 mM MOPS pH 7.5, 100 mM NaCl, 20 mM NaF, 10 mM MgCl<sub>2</sub>, 1  $\mu$ M CaCl<sub>2</sub>, 1 mM DTT, and 200 mM octyl glucoside by vigorous mixing. The lipid/detergent solution was split into 5  
20 mL aliquots and stored at -80 °C.

#### 4x Liposome Preparation

The lipid composition was 5 mol% DAG (Avanti 800811O), 40 mol% PS (Avanti 840035P), and 55 mol% PC (Avanti 850457) at a total lipid concentration of 15.2 mg/mL  
25 for the 4x liposome solution. The PC, DAG, and PS were dissolved in chloroform, combined, and dried in vacuo to a thin film. The lipids were hydrated to 20 mM in 50 mM MOPS pH 7.5, 100 mM NaCl, 5 mM MgCl<sub>2</sub>, and were freeze-thawed five times. The lipid suspension was extruded through a 100 nm polycarbonate filter eleven times. Dynamic light scattering was carried out to confirm liposome size (50-60 nm radius).  
30 The liposome preparation was stored at 4 °C for as long as four weeks.

### Baculovirus Expression of Human DGK $\alpha$ and DGK $\zeta$

Human DGK-alpha-TVMV-His-pFBgate and human DGK-zeta-transcript variant-2-TVMV-His-pFBgate baculovirus samples were generated using the Bac-to-Bac baculovirus expression system (Invitrogen) according to the manufacturer's protocol.

5 The DNA used for expression of DGK-alpha and DGK-zeta have SEQ ID NOs: 1 and 3, respectively. Baculovirus amplification was achieved using infected Sf9 cells at 1:1500 virus/cell ratios, and grown for 65 hours at 27 °C post-transfection.

The expression scale up for each protein was carried out in the Cellbag 50L WAVE-Bioreactor System 20/50 from GE Healthcare Bioscience. 12 L of  $2 \times 10^6$  10 cells/mL Sf9 cells (Expression System, Davis, CA) grown in ESF921 insect medium (Expression System) were infected with virus stock at 1:200 virus/cell ratios, and grown for 66-68 hours at 27 °C post-infection. The infected cell culture was harvested by centrifugation at 2000 rpm for 20 min 4 °C in a SORVALL® RC12BP centrifuge. The cell pellets were stored at -70 °C until purification.

15

### Purification of human DGK-alpha and DGK-zeta

Full length human DGK $\alpha$  and DGK $\zeta$ , each expressed containing a TVMV-cleavable C-terminal Hexa-His tag sequence (SEQ ID NOs: 2 and 4, respectively) and produced as described above, were purified from Sf9 baculovirus-infected insect cell 20 paste. The cells were lysed using nitrogen cavitation method with a nitrogen bomb (Parr Instruments), and the lysates were clarified by centrifugation. The clarified lysates were purified to ~90 % homogeneity, using three successive column chromatography steps on an ÄKTA Purifier Plus system. The three steps column chromatography included nickel affinity resin capture (i.e. HisTrap FF crude, GE Healthcare), followed by size exclusion 25 chromatography (i.e. HiLoad 26/600 Superdex 200 prep grade, GE Healthcare for DGK-alpha, and HiPrep 26/600 Sephacryl S 300\_HR, GE Healthcare for DGK-zeta). The third step was ion exchange chromatography, and differed for the two isoforms. DGK $\alpha$  was polished using Q-Sepharose anion exchange chromatography (GE Healthcare). DGK $\zeta$  was polished using SP Sepharose cation exchange chromatography (GE Healthcare). The 30 proteins were delivered at concentrations of  $\geq 2$  mg/mL. The formulation buffers were identical for both proteins: 50 mM Hepes, pH 7.2, 500 mM NaCl, 10 % v/v glycerol, 1

mM TCEP, and 0.5 mM EDTA.

#### Assay 2: In vitro DGK Inhibition Assays – Method B

The DGK $\alpha$  and DGK $\zeta$  reactions were performed using either extruded liposome  
5 (DGK $\alpha$  and DGK $\zeta$  LIPGLO assays) or detergent/lipid micelle substrate (DGK $\alpha$  and  
DGK $\zeta$  assays). The reactions were carried out in 50 mM MOPS pH 7.5, 100 mM NaCl,  
10 mM MgCl<sub>2</sub>, 1  $\mu$ M CaCl<sub>2</sub>, and 1 mM DTT (assay buffer). The reactions using a  
detergent/lipid micelle substrate also contained 50 mM octyl B-D-glucopyranoside. The  
lipid substrate concentrations were 11 mM PS and 1 mM DAG for the detergent/lipid  
10 micelle reactions. The lipid substrate concentrations were 2 mM PS, 0.25 mM DAG, and  
2.75 mM PC for the extruded liposome reactions (5 mM total lipid). The reactions were  
carried out in 150  $\mu$ M ATP. The enzyme concentrations for the DGK $\alpha$  and DGK $\zeta$  were  
5 nM.

The compound inhibition studies were carried out as follows: 25 nL droplets of  
15 each test compound (top concentration 10 mM with 11 point, 3-fold dilution series for  
each compound) solubilized in DMSO were transferred to wells of a white 1536 well  
plate (Corning 3725). A 5 mL enzyme/lipid substrate solution at 2x final reaction  
concentration was prepared by combining 2.5 mL 4x enzyme solution (20 nM DGK $\alpha$  or  
DGK $\zeta$  (prepared as described below) in assay buffer) and 2.5 mL of either 4x liposome or  
20 4x detergent/lipid micelle solution (compositions described below) and incubated at room  
temperature for 10 minutes. Next, 1  $\mu$ L 2x enzyme/ lipid substrate solution was added to  
wells containing the test compound and reactions were initiated with the addition of 1  $\mu$ L  
300  $\mu$ M ATP. The reactions were allowed to proceed for 2 hr, after which 2  $\mu$ L Glo  
Reagent (Promega V9101) was added and incubated for 40 minutes. Next, 4  $\mu$ L Kinase  
25 Detection Reagent was added and incubated for 30 minutes. Luminescence was recorded  
using an EnVision microplate reader. The percent inhibition was calculated from the  
ATP conversion generated by no enzyme control reactions for 100 % inhibition and  
vehicle-only reactions for 0 % inhibition. The compounds were evaluated at 11  
concentrations to determine IC<sub>50</sub>.

30

#### 4x Detergent/lipid Micelle Preparation

The detergent/lipid micelle was prepared by combining 15 g phosphatidylserine (Avanti 840035P) and 1 g diacylglycerol (800811O) and dissolving into 150 mL chloroform in a 2 L round bottom flask. Chloroform was removed under high vacuum by rotary evaporation. The resulting colorless, tacky oil was resuspended in 400 mL 50 mM MOPS pH 7.5, 100 mM NaCl, 20 mM NaF, 10 mM MgCl<sub>2</sub>, 1 μM CaCl<sub>2</sub>, 1 mM DTT, and 200 mM octyl glucoside by vigorous mixing. The lipid/detergent solution was split into 5 mL aliquots and stored at -80 °C.

#### 2x Liposome Preparation

The lipid composition was 5 mol% DAG (Avanti 800811O), 40 mol% PS (Avanti 840035P), and 55 mol% PC (Avanti 850457) at a total lipid concentration of 7-8 mg/mL for the liposome solution. The PC, DAG, and PS were dissolved in chloroform, combined, and dried in vacuo to a thin film. The lipids were hydrated to 20 mM in 50 mM MOPS pH 7.5, 100 mM NaCl, 5 mM MgCl<sub>2</sub>, and were freeze-thawed five times. The lipid suspension was extruded through a 100 nm polycarbonate filter 10-12 times. Dynamic light scattering was carried out to confirm liposome size (50-60 nm radius). The liposome preparation was stored at 4 °C for as long as four weeks.

#### Baculovirus Expression of near full length Human DGK $\alpha$ and full length DGK $\zeta$

Human MA-hDGK $\alpha$ -(S9-S727)-Ct-TVMV-His-pFBgate and full length human DGK- $\zeta$ -transcript variant-2-TVMV-His-pFBgate baculovirus samples were generated using the Bac-to-Bac baculovirus expression system (Invitrogen) according to the manufacturer's protocol (note: MA- in name of DGK $\alpha$  reagents indicates two extra amino acids added prior to Ser-9). The DNA used for expression of the DGK- $\alpha$ (9-727) and DGK- $\zeta$  have SEQ ID NOS: 5 and 3, respectively. Baculovirus amplification was achieved using infected Sf9 cells at 1:1500 virus/cell ratios, and grown for 65 hours at 27 °C post-transfection.

The expression scale up for the near full length DGK- $\alpha$ (9-727) protein was carried out in 2 L flasks, and the full length DGK $\zeta$  was done using a Cellbag 50 L WAVE-Bioreactor System 20/50 from GE Healthcare Bioscience. The proteins were expressed at different volumes using similar conditions. For expression of DGK $\alpha$ (9-727), 2 x 2 L

flasks each containing 0.8 L final volume of culture media were used, and DGK $\zeta$  was grown at 12 L scale in a 50 L Cellbag. For each, an initial density of  $2 \times 10^6$  cells/mL Sf9 cells (Expression System, Davis, CA) was seeded in ESF921 insect medium (Expression System), infected with virus stock at 1:200 virus/cell ratios, and grown for 66-68 hours at 27 °C post-infection. The infected cell cultures were harvested by centrifugation at 2000 rpm for 20 min 4 °C in a SORVALL® RC12BP centrifuge. The cell pellets were stored at -80 °C until purification.

#### Purification of human DGK-alpha and DGK-zeta

Human DGK $\alpha$ (9-727) and full length DGK $\zeta$ , each expressed containing a TVMV-cleavable C-terminal Hexa-His tag sequence (SEQ ID NOs: 2 and 4, respectively) and produced as described above, were purified from Sf9 baculovirus-infected insect cell paste. The cell pastes were thawed and suspended in buffer (50 mM HEPES, pH 7.2, 300 mM NaCl, 10% v/v glycerol, 1 mM TCEP containing benzonase and protease inhibitors), to 1:10 v/v of original culture volume. Lysis was accomplished using the nitrogen cavitation method with a nitrogen bomb (Parr Instruments), and the lysates were clarified by high speed centrifugation. The clarified lysates were purified to ~90% homogeneity, using two or three successive column chromatography steps, respectively, on an ÄKTA Purifier Plus system. Both isoforms were purified by nickel affinity purification with imidazole gradient elution (i.e. HisTrap FF, GE Healthcare), followed by size exclusion chromatography (i.e. HiLoad 26/600 Superdex 200 prep grade, GE Healthcare, for DGK $\alpha$ (9-727), and HiPrep 26/600 Sephacryl S 300 HR, GE Healthcare, for DGK $\zeta$ ). These two steps yielded DGK $\alpha$ (9-727) at >90% purity. Achieving similar purity for full length DGK $\zeta$  required a third step, employing cation exchange chromatography (SP Sepharose FF, GE Healthcare), and eluting with a NaCl gradient. The final formulation buffers were similar for both proteins, with DGK $\alpha$ (9-727) prepared in 50 mM Hepes, pH 7.3, 300 mM NaCl, 10% v/v glycerol, and 1 mM TCEP, and full length DGK $\zeta$  prepared in 50 mM Hepes, pH 7.3, 500 mM NaCl, 5% v/v glycerol, and 1 mM TCEP. The proteins were concentrated to 1-2 mg/mL, flash frozen, and kept at -80 °C for long term storage.

30

Assay 3: Raji CD4 T cell IL2 Assay

A 1536-well IL-2 assay was performed in 4  $\mu$ L volume using pre-activated CD4 T cells and Raji cells. Prior to the assay, CD4 T cells were pre-activated by treatment with  $\alpha$ -CD3,  $\alpha$ -CD28 and PHA at 1.5  $\mu$ g/mL, 1  $\mu$ g/mL, and 10  $\mu$ g/mL, respectively. Raji cells were treated with Staphylococcal enterotoxin B (SEB) at 10,000 ng/mL. Serially diluted compounds were first transferred to 1536-well assay plate (Corning, #3727), followed by addition of 2  $\mu$ L of pre-activated CD4 T cells (final density at 6000 cells/well) and 2  $\mu$ L of SEB-treated Raji cells (2000 cells/well). After 24 hours incubation at a 37  $^{\circ}$ C/5% CO<sub>2</sub> incubator, 4  $\mu$ L of IL-2 detection reagents were added to the assay plate (Cisbio, #64IL2PEC). The assay plates were read on an Envision reader. To assess compound cytotoxicity, either Raji or CD4 T cells were incubated with the serially diluted compounds. After 24 hours incubation, 4  $\mu$ L of Cell Titer Glo (Promega, #G7572) were added, and the plates were read on an Envision reader. The 50 % effective concentration (IC<sub>50</sub>) was calculated using the four-parameter logistic formula  $y = A + ((B - A) / (1 + ((C/x)^D)))$ , where A and B denote minimal and maximal % activation or inhibition, respectively, C is the IC<sub>50</sub>, D is hill slope and x represent compound concentration.

#### Assay 4: CellTiter-Glo CD8 T Cell Proliferation Assay

Frozen naïve human CD8 T cells were thawed in RPMI+10 % FBS, incubated for 2 h in 37  $^{\circ}$ C, and counted. The 384-well tissue culture plate was coated overnight at 4  $^{\circ}$ C with 20  $\mu$ L anti-human CD3 at 0.1  $\mu$ g/mL in plain RPMI, which was removed off the plate before 20k/40  $\mu$ L CD8 T cells with 0.5  $\mu$ g/mL soluble anti-human CD28 were added to each well. The compounds were echoed to the cell plate immediately after the cells were plated. After 72 h incubation at 37  $^{\circ}$ C incubator, 10  $\mu$ L CellTiter-glo reagent (Promega catalog number G7570) was added to each well. The plate was vigorously shaken for 5 mins, incubated at room temperature for another 15 mins and read on Envision for CD8 T cell proliferation. In analysis, 0.1  $\mu$ g/mL anti-CD3 and 0.5  $\mu$ g/mL anti-CD28 stimulated CD8 T cell signal was background. The reference compound, 8-(4-(bis(4-fluorophenyl)methyl) piperazin-1-yl)-5-methyl-7-nitro-6-oxo-5,6-dihydro-1,5-naphthyridine-2-carbonitrile, at 3  $\mu$ M was used to set the 100 % range and EC<sub>50</sub> was at absolute 50 % to normalize the data.

#### Assay 5: DGK AP1-Reporter Assay

The Jurkat AP1-luciferase Reporter was generated using the Cignal Lenti AP1 Reporter (luc) Kit from SABiosciences (CLS-011L).

5           The compounds were transferred from an Echo LDV plate to individual wells of a 384-well plate (white, solid-bottom, opaque PE CulturPlate 6007768) using an Echo550 instrument. The sample size was 30 nL per well; and one destination plate per source plate. The cell suspensions were prepared by transferring 40 mL cells (2x 20 mL) to clean 50 mL conical tubes. The cells were concentrated by centrifugation (1200 rpm; 5  
10 mins; ambient temperature). The supernatant was removed and all cells were suspended in RPMI (Gibco 11875) +10 % FBS to make a  $1.35 \times 10^6$  cells/ml concentration. The cells were added manually using a multi-channel pipette, 30  $\mu$ L/well of cell suspension to a 384-well TC plate containing the compounds,  $4.0 \times 10^4$  cells per well. The cell plates were incubated for 20 minutes at 37 °C and 5% CO<sub>2</sub>.

15           During the incubation, anti-CD3 antibody ( $\alpha$ CD3) solutions were prepared by mixing 3  $\mu$ L  $\alpha$ CD3 (1.3 mg/mL) with 10 mL medium [final conc = 0.4  $\mu$ g/mL]. Next, 1.5  $\mu$ L  $\alpha$ CD3 (1.3 mg/mL) was mixed with 0.5 mL medium [final conc = 4  $\mu$ g/ml]. After 20 minutes, 10  $\mu$ L medium was added to all wells in column 1, wells A to M, and 10  $\mu$ L  $\alpha$ CD3 (4ug/mL) per well was added in column 1, rows N to P for reference. Then using a  
20 multi-channel pipette, 10  $\mu$ L  $\alpha$ CD3 (0.4ug/mL) per well was added. The  $\alpha$ CD3 stimulated +/- compound-treated cells were incubated at 37 °C, 5% CO<sub>2</sub> for 6 hours.

          During this incubation period, Steady-Glo (Promega E2520) reagent was slowly thawed to ambient temperature. Next, 20  $\mu$ L Steady-Glo reagent per well was added using a multi-drop Combi-dispenser. Bubbles were removed by centrifugation (2000  
25 rpm, ambient temperature, 10 secs). The cells were incubated at room temperature for 5 minutes. Samples were characterized by measuring the Relative Light Units (RLU) with an using Envision Plate Reader Instrument on a luminescence protocol. The data was analyzed using the reference compound, 8-(4-(bis(4-fluorophenyl)methyl)piperazin-1-yl)-5-methyl-7-nitro-6-oxo-5,6-dihydro-1,5-naphthyridine-2-carbonitrile, to normalize 100 %  
30 inhibition.

#### Assay 6: Murine Cytotoxic T Lymphocyte Assay

An antigen-specific cytolytic T-cell (CTL) assay was developed to evaluate functionally the ability of DGK $\alpha$  and DGK $\zeta$  inhibitors to enhance effector T cell mediated tumor cell killing activity. CD8<sup>+</sup> T-cells isolated from the OT-1 transgenic mouse recognize antigen presenting cells, MC38, that present the ovalbumin derived peptide SIINFEKL. Recognition of the cognate antigen initiates the cytolytic activity of the OT-1 antigen-specific CD8<sup>+</sup> T cells.

Functional CTL cells were generated as follows: OT-1 splenocytes from 8-12 week old mice were isolated and expanded in the presence of the SIINFEKL peptide at 1  $\mu$ g/mL and mIL2 at 10 U/mL. After three days, fresh media with mIL2 U/ml was added. On day 5 of the expansion, the CD8<sup>+</sup> T cells were isolated and ready for use. Activated CTL cells may be stored frozen for 6 months. Separately, one million MC38 tumor cells were pulsed with 1  $\mu$ g/mL of SIINFEKL-OVA peptide for 3 hours at 37 °C. The cells were washed (3X) with fresh media to remove excess peptide. Finally, CTL cells that were pretreated with DGK inhibitors for 1 hour in a 96-well U bottom plate were combined with the antigen loaded MC38 tumor cells at a 1:10 ratio. The cells were then spun at 700 rpm for 5 min and placed in an incubator overnight at 37 °C. After 24 hours, the supernatant was collected for analysis of IFN- $\gamma$  cytokine levels by AlphaLisa purchased from Perkin Elmer.

#### Assay 7: PHA Proliferation Assay

Phytohaemagglutinin (PHA)-stimulated blast cells from frozen stocks were incubated in RPMI medium (Gibco, ThermoFisher Scientific, Waltham, MA) supplemented with 10 % fetal bovine serum (Sigma Aldrich, St. Louis, MO) for one hour prior to adding to individual wells of a 384-well plate (10,000 cells per well). The compounds were transferred to individual wells of a 384-well plate and the treated cells are maintained at 37 °C, 5% CO<sub>2</sub> for 72 h in culture medium containing human IL2 (20 ng/mL) prior to measuring growth using MTS reagent [3-(4,5-dimethyl-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] following manufacturer's instructions (Promega, Madison, WI). Percent inhibition was calculated comparing values between IL2 stimulated (0 % inhibition) and unstimulated control (100 %

inhibition). Inhibition concentration (IC<sub>50</sub>) determinations were calculated based on 50 % inhibition on the fold-induction between IL2 stimulated and unstimulated treatments.

#### Assay 8: Human CD8 T cells IFN- $\gamma$ Assay

5 Frozen naïve human CD8 T cells were thawed in AIM-V media, incubated for 2 h in 37 °C, and counted. The 384-well tissue culture plate was coated overnight at 4 °C with 20  $\mu$ L anti-human CD3 at 0.05  $\mu$ g/mL in PBS, which was removed off the plate before 40,000 cells per 40 microliters CD8 T cells with 0.1  $\mu$ g/mL soluble anti-human CD28 were added to each well. The compounds were transferred using an Echo liquid  
10 handler to the cell plate immediately after the cells were plated. After 20 h incubation at 37 °C incubator, 3 microliters per well supernatants transferred into a new 384-well white assay plate for cytokine measurement.

Interferon- $\gamma$  (IFN- $\gamma$ ) was quantitated using the AlphaLISA kit (Cat#AL217) as described by the manufacturer manual (Perkin Elmer). The counts from each well were  
15 converted to IFN- $\gamma$  concentration (pg/mL). The compound EC<sub>50</sub> values were determined by setting 0.05  $\mu$ g/mL anti-CD3 plus 0.1  $\mu$ g/mL anti-CD28 as the baseline, and co-stimulation of 3  $\mu$ M of the reference compound, 8-(4-(bis(4-fluorophenyl)methyl)piperazin-1-yl)-5-methyl-7-nitro-6-oxo-5,6-dihydro-1,5-naphthyridine-2-carbonitrile, with anti-CD3 plus anti-CD28 as 100 % activation.

20

#### Assay 9: Human CD8 T cells pERK Assay

Frozen naïve human CD8 T cells were thawed in AIM-V media, incubated for 2 h in 37 °C, and counted. The CD8 positive T cells were added to 384-well tissue culture plate at 20,000 cells per well in AIM-V media. One compound was added to each well,  
25 then bead bound anti-human CD3 and anti-CD28 mAb were added at final concentration of 0.3  $\mu$ g/mL. The cells were incubated at 37 °C for 10 minutes. The reaction was stopped by adding lysis buffer from the AlphaLISA Surefire kit. (Perkin Elmer, cat# ALSU-PERK-A). Lysate (5  $\mu$ L per well) was transferred into a new 384-well white assay plate for pERK activation measurement.

30 Compound EC<sub>50</sub> was determined as setting anti-CD3 plus anti-CD28 as baseline, and co-stimulation of 3  $\mu$ M 8-(4-(bis(4-fluorophenyl)methyl)piperazin-1-yl)-5-methyl-7-

nitro-6-oxo-5,6-dihydro-1,5-naphthyridine-2-carbonitrile with anti-CD3 plus anti-CD28 as 100 % activation.

Assay 10: Human Whole Blood IFN- $\gamma$  Assay

- 5 Human venous whole blood (22.5  $\mu$ L per well), obtained from healthy donors, was pre-treated with compounds for one hour at 37 °C in a humidified 95% air/5% CO<sub>2</sub> incubator. The blood was stimulated with 2.5  $\mu$ L anti-human CD3 and anti-CD28 mAb at a final concentration of 1  $\mu$ g/mL each for 24 hours at 37 °C. IFN- $\gamma$  in the supernatants was measured using Alphascreen kit (Cat#AL217).
- 10 Compound EC<sub>50</sub> determined as setting anti-CD3 plus anti-CD28 as baseline, and co-stimulation of 3  $\mu$ M of the reference compound, 8-(4-(bis(4-fluorophenyl)methyl)piperazin-1-yl)-5-methyl-7-nitro-6-oxo-5,6-dihydro-1,5-naphthyridine-2-carbonitrile, with anti-CD3 plus anti-CD28 as 100 % activation.

15 Assay 11: DGK Human Whole Blood pERK Assay

- Human whole blood ERK phosphorylation assay was performed with human venous whole blood obtained from healthy donors (drawn with Heparin as anti-coagulant). Serial dilutions of compounds (11 points, 3-fold) in DMSO were added to 384 well plates at 20 nL/well using an ECHO 550 acoustic dispenser (Labcyte) to achieve
- 20 final starting concentration of 20  $\mu$ M in assay. Heparinized human whole blood was added to the compound plate at 9  $\mu$ L per well and incubated for one hour at 37 °C in a humidified 95%, air/5% CO<sub>2</sub> incubator. After one hour of compound incubation, 1  $\mu$ L of human anti-CD3 antibody (in-house) in the presence of cross-linking antibody goat anti-mouse IgG (4  $\mu$ g/mL) was added to the well at 1  $\mu$ g/mL final concentration for
- 25 stimulation of pathway and additionally incubated for 15 minutes at 37 °C. Stimulation was stopped by adding 90  $\mu$ L Fix/Lyse buffer (BD 558049). Cells were washed and stained with anti-CD8 PE (BD 555635) antibodies for 60 minutes at room temperature, washed again, and permeabilized on ice using Perm III buffer (BD 558050) for 30
- 30 minutes. Cells were then stained with an Alexa Fluor® 647 anti-ERK1/2 Phospho (Thr202/Tyr204) Antibody (Biolegend 675504) for 60 minutes at 1:50 dilution. Samples were washed and resuspended in dPBS containing 1% BSA (dPBS, Gibco 14190136; BSA, Sigma-Aldrich A9205). Samples analyzed using the Intellicyt® iQue Screener

PLUS. The pERK activation was quantitated by the percentage of pERK positive population within CD8 positive population. Calculations of compound potencies were based on internal compound at 20  $\mu$ M concentration as a 100% activation, and anti-CD3 control as a 0% activation.

5

Nucleotide sequence encoding hDGK $\alpha$ -(M1-S735)-Ct-TVMV-His:

```

1   ATGGCCAAGG AGAGGGGCCT AATAAGCCCC AGTGATTTTG CCCAGCTGCA
51  AAAATACATG GAATACTCCA CCAAAAAGGT CAGTGATGTC CTAAAGCTCT
101 TCGAGGATGG CGAGATGGCT AAATATGTCC AAGGAGATGC CATTGGGTAC
10  151 GAGGGATTCC AGCAATTCCT GAAAATCTAT CTCGAAGTGG ATAATGTTCC
201 CAGACACCTA AGCCTGGCAC TGTTTCAATC CTTTGAGACT GGTCACTGCT
251 TAAATGAGAC AAATGTGACA AAAGATGTGG TGTGTCTCAA TGATGTTTCC
301 TGCTACTTTT CCCTTCTGGA GGGTGGTTCG CCAGAAGACA AGTTAGAATT
351 CACCTTCAAG CTGTACGACA CGGACAGAAA TGGGATCCTG GACAGCTCAG
15  401 AAGTGGACAA AATTATCCTA CAGATGATGC GAGTGGCTGA ATACCTGGAT
451 TGGGATGTGT CTGAGCTGAG GCCGATTCCT CAGGAGATGA TGAAAGAGAT
501 TGACTATGAT GGCAGTGGCT CTGTCTCTCA AGCTGAGTGG GTCCGGGCTG
551 GGGCCACCAC CGTGCCACTG CTAGTGTCTG TGGGTCTGGA GATGACTCTG
601 AAGGACGACG GACAGCACAT GTGGAGGCC CAGAGGTTCC CCAGACCAGT
20  651 CTA CTGCAAT CTGTGCGAGT CAAGCATTGG TCTTGCAAAA CAGGGACTGA
701 GCTGTAACCT CTGTAAGTAC ACTGTTCCAG ACCAGTGTGC CATGAAAGCC
751 CTGCCTTGTG AAGTCAGCAC CTATGCCAAG TCTCGGAAGG ACATTGGTGT
801 CCAATCACAT GTGTGGGTGC GAGGAGGCTG TGAGTCCGGG CGCTGCGACC
851 GCTGTCAAG AAAGATCCGG ATCTACCACA GTCTGACCGG GCTGCATTGT
25  901 GTATGGTGCC ACCTAGAGAT CCACGATGAC TGCCTGCAAG CGGTGGGCCA
951 TGAGTGTGAC TGTGGGCTGC TCCGGGATCA CATCCTGCCT CCATCTTCCA
1001 TCTATCCCAG TGTCTGGGCC TCTGGACCGG ATCGTAAAAA TAGCAAAACA
1051 AGCCAGAAGA CCATGGATGA TTTAAATTTG AGCACCTCTG AGGCTCTGCG
1101 GATTGACCCT GTTCCTAACA CCCACCCACT TCTCGTCTTT GTCAATCCTA
30  1151 AGAGTGGCGG GAAGCAGGGG CAGAGGGTGC TCTGGAAGTT CCAGTATATA
1201 TTAAACCCTC GACAGGTGTT CAACCTCCTA AAGGATGGTG CTGAGATAGG
1251 GCTCCGATTA TTCAAGGATG TTCCTGATAG CCGGATTTTG GTGTGTGGTG
1301 GAGACGGCAC AGTAGGCTGG ATTCTAGAGA CCATTGACAA AGCTAACTTG
1351 CCAGTTTTGC CTCCTGTTGC TGTGTTGCC CTGGGTACTG GAAATGATCT
35  1401 GGCTCGATGC CTAAGATGGG GAGGAGGTTA TGAAGGACAG AATCTGGCAA
1451 AGATCCTCAA GGATTTAGAG ATGAGTAAAG TGGTACATAT GGATCGATGG
1501 TCTGTGGAGG TGATACCTCA ACAAACCTGAA GAAAAAAGTG ACCCAGTCCC
1551 CTTTCAAATC ATCAATAACT ACTTCTCTAT TGGCGTGGAT GCCTCTATTG
1601 CTCATCGATT CCACATCATG CGAGAGAAAT ATCCGGAGAA GTTCAACAGC
40  1651 AGAATGAAGA ACAAGCTATG GTACTTCGAA TTTGCCACAT CTGAATCCAT
1701 CTTCTCAACA TGCAAAAAGC TGGAGGAGTC TTTGACAGTT GAGATCTGTG
1751 GGAAACCGCT GGATCTGAGC AACCTGTCCC TAGAAGGCAT CGCAGTGCTA
1801 AACATCCCTA GCATGCATGG TGGCTCCAAC CTCTGGGGTG ATACCAGGAG
1851 ACCCCATGGG GATATCTATG GGATCAACCA GGCCTTAGGT GCTACAGCTA
45  1901 AAGTCATCAC CGACCCTGAT ATCCTGAAAA CCTGTGTACC AGACCTAAGT
1951 GACAAGAGAC TGGAAAGTGGT TGGGCTGGAG GGTGCAATTG AGATGGGCCA
2001 AATCTATACC AAGCTCAAGA ATGCTGGACG TCGGCTGGCC AAGTGTCTTG
2051 AGATCACCTT CCACACCACA AAAACCCTTC CCATGCAAAT TGACGGAGAA
2101 CCCTGGATGC AGACGCCCTG TACAATCAAG ATCACCACA AGAACCAGAT
50  2151 GCCCATGCTC ATGGGCCAC CCCCCGCTC CACCAATTTT TTTGGCTTCT
2201 TGAGCGGATC CTCGGAGACA GTGCGGTTTC AGGGACACCA CCACCATCAC
2251 CACTGA

```

(SEQ ID NO: 1)

Amino acid sequence of hDGK $\alpha$ -(M1-S735)-Ct-TVMV-His:

0001 MAKERGLISP SDFAQLQKYM EYSTKKVSDV LKLFEDGEMA KYVQGDAIGY EGFQQFLKIY 0060  
 0061 LEVDNVPRHL SLALFQSFET GHCLNETNVT KDVVCLNDVS CYFSLLEGGR PEDKLEFTFK 0120  
 5 0121 LYDTRNGIL DSSEVDKIIL QMMRVAEYLD WDVSELRPIL QEMMKEIDYD GSGSVSQAEW 0180  
 0181 VRAGATTVPL LVLLGLEMTL KDDGQHMWRP KRFRPVVYCN LCESSIGLGK QGLSCLNCKY 0240  
 0241 TVHDQCAMKA LPCEVSTYAK SRKDIGVQSH VWVRGGCESG RCDRCQKKIR IYHSLTGLHC 0300  
 0301 VWCHLEIHDD CLQAVGHECD CGLLRDHILP PSSIYPSVLA SGPDRKNSKT SQKTMDDLNL 0360  
 0361 STSEALRIDP VPNTHPLLVF VNPKSGGKQG QRVLWKFQYI LNPRQVFNLL KDGPEIGLRL 0420  
 10 0421 FKDVPDSRIL VCGGDGTVGW ILETIDKANL PVLPPVAVLP LGTGNDLARC LRWGGGYEGQ 0480  
 0481 NLAKILKDL ESKSVVHMDRW SVEVIPQOTE EKSDPVPFQI INNYFSIGVD ASIAHRFHIM 0540  
 0541 REKYPEKFNS RMKNKLWYFE FATSESIFST CKKLEESLTV EICGKPLDLS NLSLEGI AVL 0600  
 0601 NIPSMHGGSN LWGDTRRPHG DIYGINQALG ATAKVITDPD ILKTCVPDLS DKRLEVVGLE 0660  
 0661 GAIEMGQIYT KLKNAGRRLA KCSEITFHTT KTLPMQIDGE PWMQTPCTIK ITHKNQMFML 0720  
 15 0721 MGPPPRSTNF FGFLSGSSET VRFQGHHHH H 0751

(SEQ ID NO: 2)

Nucleotide sequence encoding hDGK $\zeta$ -(M1-A928)-transcript variant-2 Ct-TVMV-His:

1 ATGGAGCCGC GGGACGGTAG CCCCAGGCC CGGAGCAGCG ACTCCGAGTC  
 20 51 GGCTTCCGCC TCGTCCAGCG GCTCCGAGCG CGACGCCGGT CCCGAGCCGG  
 101 ACAAGGCGCC GCGGCGACTC AACAAAGCGGC GCTTCCCGGG GCTGCGGCTC  
 151 TTCGGGCACA GGAAAGCCAT CACGAAGTCG GGCCTCCAGC ACCTGGCCCC  
 201 CCCTCCGCCC ACCCCTGGGG CCCCCTGCAG CGAGTCAGAG CGGCAGATCC  
 25 251 GGAGTACAGT GGACTGGAGC GAGTCAGCGA CATATGGGGA GCACATCTGG  
 301 TTCGAGACCA ACGTGTCCGG GGACTTCTGC TACGTTGGGG AGCAGTACTG  
 351 TGTAGCCAGG ATGCTGCAGA AGTCAGTGT CCGAAGAAAG TGCGCAGCCT  
 401 GCAAGATTGT GGTGCACACG CCCTGCATCG AGCAGCTGGA GAAGATAAAT  
 451 TTCCCGTGTA AGCCGTCCCTT CCGTGAATCA GGCTCCAGGA ATGTCCCGCA  
 501 GCCAACCTTT GTACGGCACC ACTGGGTACA CAGACGACGC CAGGACGGCA  
 30 551 AGTGTCCGCA CTGTGGGAAG GGATTCCAGC AGAAGTTCAC CTTCCACAGC  
 601 AAGGAGATTG TGGCCATCAG CTGCTCGTGG TGCAAGCAGG CATAACACAG  
 651 CAAGGTGTCC TGCTTCATGC TGCAGCAGAT CGAGGAGCCG TGCTCGCTGG  
 701 GGGTCCACGC AGCCGTGGTC ATCCC GCCCA CCTGGATCCT CCGCGCCCGG  
 751 AGGCCCCAGA ATACTCTGAA AGCAAGCAAG AAGAAGAAGA GGGCATCCTT  
 35 801 CAAGAGGAAG TCCAGCAAGA AAGGGCCTGA GGAGGGCCGC TGGAGACCTT  
 851 TCATCATCAG GCCCAGCCCT TCCCCTGCTCA TGAAGCCCT GCTGGTGTCTT  
 901 GTGAACCCCA AGAGTGGGGG CAACCAGGGT GCAAAGATCA TCCAGTCTTT  
 951 CCTCTGGTAT CTCAATCCCC GACAAGTCTT CGACCTGAGC CAGGGAGGGC  
 1001 CCAAGGAGGC GCTGGAGATG TACCGCAAAG TGCACAACCT GCGGATCCTG  
 40 1051 GCGTGCAGGG GCGACGGCAC GGTGGGCTGG ATCCTCTCCA CCCTGGACCA  
 1101 GCTACGCCCTG AAGCCGCCAC CCCCTGTTGC CATCCTGCC CTGGGTACTG  
 1151 GCAACGACTT GGCCCGAAC CTCAACTGGG GTGGGGGCTA CACAGATGAG  
 1201 CCTGTGTCCA AGATCCTCTC CCACGTGGAG GAGGGGAACG TGGTACAGCT  
 1251 GGACCGCTGG GACCTCCACG CTGAGCCCAA CCCCAGGGCA GGGCCTGAGG  
 45 1301 ACCGAGATGA AGGCGCCACC GACCGGTTGC CCCTGGATGT CTTCAACAAC  
 1351 TACTTCAGCC TGGGCTTTGA CGCCACGTC ACCCTGGAGT TCCACGAGTC  
 1401 TCGAGAGGCC AACCCAGAGA AATTCAACAG CCGCTTTCCG AATAAGATGT  
 1451 TCTACGCCGG GACAGCTTTC TCTGACTTCC TGATGGGCAG CTCCAAGGAC  
 1501 CTGGCCAAGC ACATCCGAGT GGTGTGTGAT GGAATGGACT TGACTCCCAA

```

1551      GATCCAGGAC CTGAAACCCC AGTGTGTTGT TTTCTGAAC ATCCCCAGGT
1601      ACTGTGCGGG CACCATGCCC TGGGGCCACC CTGGGGAGCA CCACGACTTT
1651      GAGCCCCAGC GGCATGACGA CGGCTACCTC GAGGTCATTG GCTTCACCAT
1701      GACGTCGTTG GCCGCGCTGC AGGTGGGCGG ACACGGCGAG CGGCTGACGC
5 1751      AGTGTGCGGA GGTGGTGCTC ACCACATCCA AGGCCATCCC GGTGCAGGTG
1801      GATGGCGAGC CCTGCAAGCT TGCAGCCTCA CGCATCCGCA TCGCCCTGCG
1851      CAACCAGGCC ACCATGGTGC AGAAGGCCAA GCGGCGGAGC GCCGCCCCCC
1901      TGCACAGCGA CCAGCAGCCG GTGCCAGAGC AGTTGCGCAT CCAGGTGAGT
1951      CGCGTCAGCA TGCACGACTA TGAGGCCCTG CACTACGACA AGGAGCAGCT
10 2001      CAAGGAGGCC TCTGTGCCGC TGGGCACTGT GGTGGTCCCA GGAGACAGTG
2051      ACCTAGAGCT CTGCCGTGCC CACATTGAGA GACTCCAGCA GGAGCCCAGT
2101      GGTGCTGGAG CCAAGTCCCC GACATGCCAG AAAGTGTCCC CCAAGTGGTG
2151      CTTCCTGGAC GCCACCACTG CCAGCCGCTT CTACAGGATC GACCGAGCCC
2201      AGGAGCACCT CAACTATGTG ACTGAGATCG CACAGGATGA GATTTATATC
15 2251      CTGGACCCCT AGTGCTGGG GGCATCGGCC CGGCCGTACC TCCCAACCCC
2301      CACTTCCCTT CTCCCCACT CACCCTGCTC ACCCACGCC CGGTCACTGC
2351      AAGGGGATGC TGCACCCCCT CAAGGTGAAG AGCTGATTGA GGCTGCCAAG
2401      AGGAACGACT TCTGTAAGCT CCAGGAGCTG CACCGAGCTG GGGGCGACCT
2451      CATGCACCGA GACGAGCAGA GTCGCACGCT CCTGCACCAC GCAGTCAGCA
20 2501      CTGGCAGCAA GGATGTGGTC CGCTACCTGC TGGACCACGC CCCCCAGAG
2551      ATCCTTGATG CGGTGGAGGA AAACGGGGAG ACCTGTTTGC ACCAAGCAGC
2601      GGCCCTGGGC CAGCGCACCA TCTGCCACTA CATCGTGGAG GCCGGGGCCT
2651      CGTTCATGAA GACAGACCAG CAGGGCGACA CTCCCCGGA CCGGGCTGAG
2701      AAGGCTCAGG ACACCGAGCT GGCCGCCTAC CTGGAGAACC GGCAGCACTA
25 2751      CCAGATGATC CAGCGGGAGG ACCAGGAGAC GGCTGTGGGA TCCTCGGAGA
2801      CAGTGCGGTT TCAGGGACAC CACCACCATC ACCACTGA

```

(SEQ ID NO: 3)

Amino acid sequence of hDGKζ-(M1-A928)-transcript variant-2 Ct-TVMV-His:

```

30 0001 MEPRDGSPEA RSSDSESASA SSSGSERDAG PEPDKAPRRL NKRRFPLRL FGHRKAITKS 0060
0061 GLQHLAPPPP TPGAPCSESE RQIRSTVDWS ESATYGEHIW FETNVSGDFC YVGEQYCVAR 0120
0121 mLQKSVSRRK CAACKIVVHT PCIEQLEKIN FRCKPSFRES GSRNVREPTF VRHHWVHRRR 0180
0181 QDGKCRHCGK GFQQKFTFHS KEIVAIKCSW CKQAYHSKVS CFMLQQIEEP CSLGVHAAVV 0240
0241 IPPTWILRAR RPQNTLKASK KKKRASFKRK SSKKGPEEGR WRPFIIRPTP SPLMKPLLVF 0300
35 0301 VNPKSGGNQG AKIIQSFLWY LNPRQVFDLS QGGPKAELEM YRKVHNLRL ACGGDGTVGW 0360
0361 ILSTLDQLRL KPPPPVAILP LGTGNDLART LNWGGGYTDE PVSILSHVE EGNVQLDRW 0420
0421 DLHAEPNPEA GPEDRDEGAT DRLPLDVENN YFSLGFDHAV TLEFHESREA NPEKFSRFR 0480
0481 NKMFYAGTAF SDFLMGSSKD LAKHIRVVCD GMDLTPKIQD LKPQC VVFLN IPRYAGTMP 0540
0541 WGHPGEHDF EPQRHDDGYL EVIGFTMTSL AALQVGGHGE RLTQCREVVL TSKAIPVQV 0600
40 0601 DGEPCKLAAS RIRIALRNQA TMVQKARRS AAPLHSDQQP VPEQLRIQVS RVSMHDYEAL 0660
0661 HYDKEQLKEA SVPLGTVVVP GDSDLELCRA HIERLQQEPD GAGAKSPTCQ KLSPKWCFD 0720
0721 ATTASRFYRI DRAQEHLNYV TEIAQDEIYI LDPELLGASA RPDLPPTSP LPTSPCSPTP 0780
0781 RSLQGDAAAP QGEELIEAAK RNDFCKLQEL HRAGGDLMHR DEQSRLLHH AVSTGSKDVV 0840
0841 RYLLDHAPPE ILDAVEENGE TCLHQAAALG QRTICHYIVE AGASLMKTDQ QGDTPRQRAE 0900
45 0901 KAQDTELAAY LENRQHYQMI QREDQETAVG SSETVRFQGH HHHHH 0945

```

(SEQ ID NO: 4)

Nucleotide sequence encoding MA-hDGK $\alpha$ -(S9-S727)-Ct-TVMV-His:

0001 ATGGCTTCCC CAAGCGACTT CGCCCAGCTG CAGAAGTACA TGGAAATACAG CACCAAGAAG 0060  
 0061 GTGTCTGACG TCCTGAAGCT GTTCGAGGAC GGTGAAATGG CTAAGTACGT CCAGGGCGAC 0120  
 0121 GCTATCGGAT ACGAGGGATT CCAGCAGTTC CTGAAGATCT ACCTGGAAGT GGACAACGTC 0180  
 5 0181 CCCAGGCACC TGTCACTGGC TCTGTTCCAG TCCTTCGAGA CTGGCCACTG CCTGAACGAA 0240  
 0241 ACCAACGTCA CTAAGGACGT GGTCTGCCTG AACGACGTGA GCTGCTACTT CTCTCTGCTG 0300  
 0301 CAGGGTGCCTA GACCAGAGCA CAAGCTGCAA TTCACCTTCA AGCTGTACGA CACTGACCCC 0360  
 0361 AACGGAATCC TGGACTCCAG CGAAGTGGAC AAGATCATCC TGCAGATGAT GCGTGTCCGCT 0420  
 0421 GAGTACCTGG ACTGGGACGT GAGCGAACTG AGGCTATCC TGCAGGAGAT GATGAAGGAA 0480  
 10 0481 ATCCGACTACG ACGGCTCTGG ATCAGTGTCC CAGGCTGAGT GGGTCCCGCG TGGTGTCTACC 0540  
 0541 ACTGTGCCAC TGCTGGTCCT GCTGGGACTG GAAATGACCC TGAAGGACGA CGGTCAGCAC 0600  
 0601 ATGTGGCGCC CAAAGCGTTT CCCCAGGCCA GTCTACTGCA ACCTGTGCGA GTCTTCAATC 0660  
 0661 GGTCTGGSCA AGCAGGGCCT GTCATGCAAC CTGTGCAAGT ACACCGTGCA CGACCAGTGC 0720  
 0721 GCTATGAAGG CCCTGCCCTG CGAGGTCTCA ACTTACGCTA AGTCCCCTAA GGACATCGGA 0780  
 15 0781 GTGCAGTCAC ACGTGTGGGT CAGGGGAGGT TCGGAATCCG GTAGATGCGA CCCTGCCAG 0840  
 0841 AAGAAGATCC GTATCTACCA CTCCCTGACC GGACTGCACT GCGTCTGGTG CCACCTGGAG 0900  
 0901 ATCCACGACG ACTGCCCTGCA GGCCGTGGGA CACGAATGCG ACTGCGGTCT GCTGCGTGAC 0960  
 0961 CACATCCTGC CTCCCTCCAG CATCTACCCT TCAGTCCCTGG CTTCCGGTCC CGACAGGAAG 1020  
 1021 AACAGCAAGA CCTCTCAGAA GACTATGGAC GACCTGAACC TGAGCACCTC TGAGGCCCTG 1080  
 20 1081 CGCATCGACC CTGTGCCCAA CACTCACCCA CTGCTGGTGT TCGTCAACCC TAAGAGCGGC 1140  
 1141 GAAAGCAGG GTCAGAGAGT CCTGTGGAAG TTCCAGTACA TCCTGAACCC ACGCCAGGTG 1200  
 1201 TTCAACCTGC TGAAGGACGG CCCTGAGATC GGACTGAGAC TGTTCAAGGA CGTGCCCGAC 1260  
 1261 TCTCGCATCC TCGTCTGCGG TGGCGACGGT ACTGTGGGAT GGATCCTGGA AACTATCGAC 1320  
 1321 AAGGCTAACC TGCCAGTGCT GCCACCTGTG GCTGTCTGTC CACTGGGAAC CGGTAACGAC 1380  
 25 1381 CTGGCTCGTT GCCTGCGTTG GGGAGGTGGC TACGAGGGAC AGAACCTGGC CAAGATCCTG 1440  
 1441 AAGGACCTGG AAATGAGCAA GGTGGTCCAC ATGGACAGAT GGTCTGTGGA GGTCATCCCA 1500  
 1501 CAGCAGACTG AGGAAAAGTC AGACCCAGTC CCTTCCAGA TCATCAACAA CTACTTCAGC 1560  
 1561 ATCGGTGTGG ACGCTTCTAT CGCCCACAGA TTCCACATCA TGCGCGAGAA GTACCCTGAA 1620  
 1621 AAGTTCAACT CCCGCATGAA GAACAAGCTG TGGTACTTCC AGTTCCGTAC CTCAGAATCC 1680  
 30 1681 ATCTTCTCAA CTTGCAAGAA GCTGGAGGAA TCCCTGACCG TCGAGATCTG CGGCAAGCCT 1740  
 1741 CTGGACCTGT CAAACCTGTC CCTGGAAGGC ATCGTGTGTC TGAACATCCC AAGCATGCAC 1800  
 1801 GGAGGTTCTA ACCTCTGGGG CGACACTAGG AGGCTCACG GTGACATCTA CGGCATCAAC 1860  
 1861 CAGGCCCTGG GAGCTACCGC CAAGGTCATC ACTGACCCCG ACATCCTGAA GACCTGCGTG 1920  
 1921 CCAGACCTGA GCGACAAGCG TCTGGAGGTG GTCGGACTGG AGGGTGCCAT CGAAATGGGC 1980  
 35 1981 CAGATCTACA CTAAGCTCAA GAACCCTCGA ACGAGACTCC CCAACTGCTC TGAGATCACC 2040  
 2041 TTCCACACCA CTAAGACTCT GCCTATGCAG ATCGACGGTG AACCCCTGGAT GCAGACCCCA 2100  
 2101 TGCACTATCA AGATCACCCA CAAGAACCAG ATGCCCATGC TGATGGGTCC TCCTCCTCGC 2160  
 2161 TCTGGATCTT CAGAAACTGT GAGGTTCCAG GGGCACACC ACCACCACCA CTGA 2214

(SEQ ID NO: 5)

40

Amino acid sequence of MA-hDGK $\alpha$ -(S9-S727)-Ct-TVMV-His:

0001 MASPSDFAQL QKYMEYSTKK VSDVCLKLFED GEMAKYVQGD AIGYEGFQQF LKIYLEVDNV 0060  
 0061 PRHLSLALFQ SFETGHCLNE TNVTKDVVCL NDVSCYFSLLE EGGRPEDKLE FTFKLYDTDR 0120  
 0121 NGILDSSEVD KIILQMMRVA EYLDWDVSEL RPILQEMMKE IDYDGSQSVS QAEWVRAGAT 0180


0181 TVPLLVLLGL EMTLKDDGQH MWRPKRFPRP VYCNLCESSI GLGKQGLSCN LCKYTVHDQC 0240  
0241 AMKALPCEVS TYAKSRKDIG VQSHVWVRGG CESGRCDRCQ KKIRIYHSLT GLHCVWCHLE 0300  
0301 IHDDCLQAVG HECDCGLLRD HILPPSSIYP SVLASGPDRK NSKTSQKTMD DLNLSTSEAL 0360  
0361 RIDPVPNTHP LLVFNPKSG GKQGQRVLWK FQYILNPRQV FNLLKDGPEI GLRLFKDVPD 0420  
5 0421 SRILVCGGDG TVGWILETID KANLPVLPPV AVLPLGTGND LARCLRWGGG YEQNLAKIL 0480  
0481 KDLEMSKVVH MDRWSVEVIP QQTEEKSDPV PFQIINNYFS IGVDASIAHR FHIMREKYPE 0540  
0541 KFNSRMKNKL WYFEFATSES IFSTCKKLEE SLTVEICGKP LDLSNLSLEG IAVLNIPSMH 0600  
0601 GGSNLWGDTR RPHGDIYGIN QALGATAKVI TDPDILKTCV PDLSDKRLEV VGLEGAIEMG 0660  
0661 QIYTKLKNAG RRLAKCSEIT FHTTKTLPMQ IDGEPWMQTP CTIKITHKNQ MPMLMGPPPR 0720  
10 0721 SGSSETVRFQ GHHHHHH 0737

(SEQ ID NO: 6)

## CLAIMS

What is claimed is:

- 5 1. A compound of Formula (I):



or a salt thereof, wherein:

- $R_1$  is H, F, Cl, Br,  $-CN$ ,  $C_{1-3}$  alkyl substituted with zero to 4  $R_{1a}$ ,  $C_{3-4}$  cycloalkyl substituted with zero to 4  $R_{1a}$ ,  $C_{1-3}$  alkoxy substituted with zero to 4  $R_{1a}$ ,
- 10  $-C(O)NR_aR_a$ ,  $-NR_aR_a$ ,  $-S(O)_nR_e$ , or  $-P(O)R_eR_e$ ;
- each  $R_{1a}$  is independently F, Cl,  $-CN$ ,  $-OH$ ,  $-OCH_3$ , or  $-NR_aR_a$ ;
- each  $R_a$  is independently H or  $C_{1-3}$  alkyl;
- each  $R_e$  is independently  $C_{3-4}$  cycloalkyl or  $C_{1-3}$  alkyl substituted with zero to 4  $R_{1a}$ ;
- $R_2$  is H,  $C_{1-3}$  alkyl substituted with zero to 4  $R_{2a}$ ,  $C_{2-3}$  alkenyl substituted with zero to 4
- 15  $R_{2a}$ , or  $C_{3-4}$  cycloalkyl substituted with zero to 4  $R_{2a}$ ;
- each  $R_{2a}$  is independently F, Cl,  $-CN$ ,  $-OH$ ,  $-O(C_{1-2}$  alkyl),  $C_{3-4}$  cycloalkyl,  $C_{3-4}$  alkenyl, or  $C_{3-4}$  alkynyl;
- $R_4$  is  $-CH_2R_{4a}$ ,  $-CH_2CH_2R_{4a}$ ,  $-CH_2CHR_{4a}R_{4d}$ ,  $-CHR_{4a}R_{4b}$ , or  $-CR_{4a}R_{4b}R_{4c}$ ;
- $R_{4a}$  and  $R_{4b}$  are independently:
- 20 (i)  $C_{1-6}$  alkyl substituted with zero to 4 substituents independently selected from F, Cl,  $-CN$ ,  $-OH$ ,  $-OCH_3$ ,  $-SCH_3$ ,  $C_{1-3}$  fluoroalkoxy,  $-NR_aR_a$ ,  $-S(O)_2R_e$ , or  $-NR_aS(O)_2R_e$ ;
- (ii)  $C_{3-6}$  cycloalkyl, heterocyclyl, phenyl, or heteroaryl, each substituted with zero to 4
- 25 substituents independently selected from F, Cl, Br,  $-CN$ ,  $-OH$ ,  $C_{1-6}$  alkyl,  $C_{1-3}$  fluoroalkyl,  $C_{1-4}$  hydroxyalkyl,  $-(CH_2)_{1-2}O(C_{1-3}$  alkyl),  $C_{1-4}$  alkoxy,  $-O(C_{1-4}$  hydroxyalkyl),  $-O(CH)_{1-3}O(C_{1-3}$  alkyl),  $C_{1-3}$  fluoroalkoxy,  $-O(CH)_{1-3}NR_cR_c$ ,

- $-\text{OCH}_2\text{CH}=\text{CH}_2$ ,  $-\text{OCH}_2\text{C}\equiv\text{CH}$ ,  $-\text{C}(\text{O})(\text{C}_{1-4} \text{ alkyl})$ ,  $-\text{C}(\text{O})\text{OH}$ ,  $-\text{C}(\text{O})\text{O}(\text{C}_{1-4} \text{ alkyl})$ ,  
 $-\text{NR}_c\text{R}_c$ ,  $-\text{NR}_a\text{S}(\text{O})_2(\text{C}_{1-3} \text{ alkyl})$ ,  $-\text{NR}_a\text{C}(\text{O})(\text{C}_{1-3} \text{ alkyl})$ ,  $-\text{NR}_a\text{C}(\text{O})\text{O}(\text{C}_{1-4} \text{ alkyl})$ ,  
 $-\text{P}(\text{O})(\text{C}_{1-3} \text{ alkyl})_2$ ,  $-\text{S}(\text{O})_2(\text{C}_{1-3} \text{ alkyl})$ ,  $-\text{O}(\text{CH}_2)_{1-2}(\text{C}_{3-6} \text{ cycloalkyl})$ ,  
 $-\text{O}(\text{CH}_2)_{1-2}(\text{morpholinyl})$ , cyclopropyl, cyanocyclopropyl, methylazetidiny,
- 5 acetylazetidiny, (*tert*-butoxycarbonyl)azetidiny, triazolyl, tetrahydropyranyl, morpholinyl, thiophenyl, methylpiperidiny, and  $\text{R}_d$ ; or
- (iii)  $\text{C}_{1-4}$  alkyl substituted with one cyclic group selected from  $\text{C}_{3-6}$  cycloalkyl, heterocyclyl, aryl, and heteroaryl, said cyclic group substituted with zero to 3 substituents independently selected from F, Cl, Br,  $-\text{OH}$ ,  $-\text{CN}$ ,  $\text{C}_{1-6}$  alkyl,  $\text{C}_{1-3}$
- 10 fluoroalkyl,  $\text{C}_{1-3}$  alkoxy,  $\text{C}_{1-3}$  fluoroalkoxy,  $-\text{OCH}_2\text{CH}=\text{CH}_2$ ,  $-\text{OCH}_2\text{C}\equiv\text{CH}$ ,  $-\text{NR}_c\text{R}_c$ ,  $-\text{NR}_a\text{S}(\text{O})_2(\text{C}_{1-3} \text{ alkyl})$ ,  $-\text{NR}_a\text{C}(\text{O})(\text{C}_{1-3} \text{ alkyl})$ ,  $-\text{NR}_a\text{C}(\text{O})\text{O}(\text{C}_{1-4} \text{ alkyl})$ , and  $\text{C}_{3-6}$  cycloalkyl;
- or  $\text{R}_{4a}$  and  $\text{R}_{4b}$  together with the carbon atom to which they are attached form a  $\text{C}_{3-6}$  cycloalkyl or a 3- to 6-membered heterocyclyl, each substituted with zero to 3  $\text{R}_f$ ;
- 15 each  $\text{R}_f$  is independently F, Cl, Br,  $-\text{OH}$ ,  $-\text{CN}$ ,  $\text{C}_{1-6}$  alkyl,  $\text{C}_{1-3}$  fluoroalkyl,  $\text{C}_{1-3}$  alkoxy,  $\text{C}_{1-3}$  fluoroalkoxy,  $-\text{OCH}_2\text{CH}=\text{CH}_2$ ,  $-\text{OCH}_2\text{C}\equiv\text{CH}$ ,  $-\text{NR}_c\text{R}_c$ , or a cyclic group selected from  $\text{C}_{3-6}$  cycloalkyl, 3- to 6-membered heterocyclyl, phenyl, monocyclic heteroaryl, and bicyclic heteroaryl, each cyclic group substituted with zero to 3 substituents independently selected from F, Cl, Br,  $-\text{OH}$ ,  $-\text{CN}$ ,  $\text{C}_{1-6}$  alkyl,  $\text{C}_{1-3}$
- 20 fluoroalkyl,  $\text{C}_{1-3}$  alkoxy,  $\text{C}_{1-3}$  fluoroalkoxy, and  $-\text{NR}_c\text{R}_c$ ;
- $\text{R}_{4c}$  is  $\text{C}_{1-6}$  alkyl or  $\text{C}_{3-6}$  cycloalkyl, each substituted with zero to 4 substituents independently selected from F, Cl,  $-\text{OH}$ ,  $\text{C}_{1-2}$  alkoxy,  $\text{C}_{1-2}$  fluoroalkoxy, and  $-\text{CN}$ ;
- $\text{R}_{4d}$  is  $-\text{OCH}_3$ ;
- each  $\text{R}_c$  is independently H or  $\text{C}_{1-2}$  alkyl;
- 25  $\text{R}_a$  is phenyl substituted with zero to 1 substituent selected from F, Cl,  $-\text{CN}$ ,  $-\text{CH}_3$ , and  $-\text{OCH}_3$ ;
- each  $\text{R}_5$  is independently F, Cl,  $-\text{CN}$ ,  $-\text{OH}$ ,  $\text{C}_{1-6}$  alkyl substituted with zero to 4  $\text{R}_g$ ,  $\text{C}_{1-3}$  alkoxy substituted with zero to 4  $\text{R}_g$ ,  $\text{C}_{2-4}$  alkenyl substituted with zero to 4  $\text{R}_g$ ,  $\text{C}_{2-4}$  alkynyl substituted with zero to 4  $\text{R}_g$ ,  $\text{C}_{3-4}$  cycloalkyl substituted with zero to 4  $\text{R}_g$ ,
- 30 phenyl substituted with zero to 4  $\text{R}_g$ , oxadiazolyl substituted with zero to 3  $\text{R}_g$ ,

pyridinyl substituted with zero to 4  $R_g$ ,  $-(CH_2)_{1-2}$ (heterocyclyl substituted with zero to 4  $R_g$ ),  $-(CH_2)_{1-2}NR_cC(O)(C_{1-4}$  alkyl),  $-(CH_2)_{1-2}NR_cC(O)O(C_{1-4}$  alkyl),  $-(CH_2)_{1-2}NR_cS(O)_2(C_{1-4}$  alkyl),  $-C(O)(C_{1-4}$  alkyl),  $-C(O)OH$ ,  $-C(O)O(C_{1-4}$  alkyl),  $-C(O)O(C_{3-4}$  cycloalkyl),  $-C(O)NR_aR_a$ , or  $-C(O)NR_a(C_{3-4}$  cycloalkyl), or two  $R_5$  attached to the same carbon atom form  $=O$ ;

5 each  $R_g$  is independently F, Cl,  $-CN$ ,  $-OH$ ,  $C_{1-3}$  alkoxy,  $C_{1-3}$  fluoroalkoxy,  $-O(CH_2)_{1-2}O(C_{1-2}$  alkyl),  $C_{3-5}$  cycloalkyl, or  $-NR_cR_c$ ;

each  $R_6$  is H, F, Cl,  $-CN$ ,  $-ClI_3$ ,  $-ClI_2F$ ,  $-ClIF_2$ ,  $-CF_3$ , or  $-OClI_3$ ;

$m$  is zero, 1, 2, or 3; and

10  $n$  is zero, 1, or 2.

2. The compound according to Claim 1 or a salt thereof, wherein:

$R_1$  is H, F, Cl, Br,  $-CN$ ,  $C_{1-3}$  alkyl substituted with zero to 4  $R_{1a}$ , cyclopropyl substituted with zero to 3  $R_{1a}$ ,  $C_{1-3}$  alkoxy substituted with zero to 3  $R_{1a}$ ,  $-C(O)NR_aR_a$ ,  $-NR_aR_a$ ,

15  $-S(O)_nCH_3$ , or  $-P(O)(CH_3)_2$ ;

each  $R_{1a}$  is independently F, Cl, or  $-CN$ ;

each  $R_a$  is independently H or  $C_{1-3}$  alkyl;

$R_2$  is H,  $C_{1-2}$  alkyl substituted with zero to 2  $R_{2a}$ , or  $C_{2-3}$  alkenyl substituted with zero to 2  $R_{2a}$ ;

20 each  $R_{2a}$  is independently F, Cl,  $-CN$ ,  $-OH$ ,  $-O(C_{1-2}$  alkyl), cyclopropyl,  $C_{3-4}$  alkenyl, or  $C_{3-4}$  alkynyl;

$R_{4a}$  and  $R_{4b}$  are independently:

(i)  $C_{1-4}$  alkyl substituted with zero to 4 substituents independently selected from F, Cl,  $-CN$ ,  $-OH$ ,  $-OCH_3$ ,  $-SCH_3$ ,  $C_{1-3}$  fluoroalkoxy, and  $-NR_aR_a$ ;

25 (ii)  $C_{3-6}$  cycloalkyl, heterocyclyl, phenyl, or heteroaryl, each substituted with zero to 4 substituents independently selected from F, Cl, Br,  $-CN$ ,  $-OH$ ,  $C_{1-6}$  alkyl,  $C_{1-3}$  fluoroalkyl,  $-CH_2OH$ ,  $-(CH_2)_{1-2}O(C_{1-2}$  alkyl),  $C_{1-4}$  alkoxy,  $-O(C_{1-4}$  hydroxyalkyl),  $-O(CH)_{1-2}O(C_{1-2}$  alkyl),  $C_{1-3}$  fluoroalkoxy,  $-O(CH)_{1-2}NR_cR_c$ ,  $-OCH_2CH=CH_2$ ,  $-OCH_2C\equiv CH$ ,  $-C(O)(C_{1-4}$  alkyl),  $-C(O)OH$ ,  $-C(O)O(C_{1-4}$  alkyl),  $-NR_cR_c$ ,

30  $-NR_aS(O)_2(C_{1-3}$  alkyl),  $-NR_aC(O)(C_{1-3}$  alkyl),  $-NR_aC(O)O(C_{1-4}$  alkyl),  $-P(O)(C_{1-2}$

alkyl)<sub>2</sub>, -S(O)<sub>2</sub>(C<sub>1-3</sub> alkyl), -O(CH<sub>2</sub>)<sub>1-2</sub>(C<sub>3-4</sub> cycloalkyl), -O(CH<sub>2</sub>)<sub>1-2</sub>(morpholinyl), cyclopropyl, cyanocyclopropyl, methylazetidiny, acetylazetidiny, (*tert*-butoxycarbonyl)azetidiny, triazolyl, tetrahydropyranyl, morpholinyl, thiophenyl, methylpiperidinyl, and R<sub>d</sub>; or

- 5 (iii) C<sub>1-3</sub> alkyl substituted with one cyclic group selected from C<sub>3-6</sub> cycloalkyl, heterocyclyl, phenyl, and heteroaryl, said cyclic group substituted with zero to 3 substituents independently selected from F, Cl, Br, -OH, -CN, C<sub>1-3</sub> alkyl, C<sub>1-2</sub> fluoroalkyl, C<sub>1-3</sub> alkoxy, C<sub>1-2</sub> fluoroalkoxy, -OCH<sub>2</sub>CH=CH<sub>2</sub>, -OCH<sub>2</sub>C≡CH, -NR<sub>c</sub>R<sub>c</sub>, -NR<sub>a</sub>S(O)<sub>2</sub>(C<sub>1-3</sub> alkyl), -NR<sub>a</sub>C(O)(C<sub>1-3</sub> alkyl), -NR<sub>a</sub>C(O)O(C<sub>1-4</sub> alkyl),  
10 and C<sub>3-4</sub> cycloalkyl;

or R<sub>4a</sub> and R<sub>4b</sub> together with the carbon atom to which they are attached, form a C<sub>3-6</sub> cycloalkyl or a 3- to 6-membered heterocyclyl, each substituted with zero to 3 R<sub>f</sub>; each R<sub>f</sub> is independently F, Cl, Br, -OH, -CN, C<sub>1-4</sub> alkyl, C<sub>1-2</sub> fluoroalkyl, C<sub>1-3</sub> alkoxy, C<sub>1-2</sub> fluoroalkoxy, -OCH<sub>2</sub>CH=CH<sub>2</sub>, -OCH<sub>2</sub>C≡CH, -NR<sub>c</sub>R<sub>c</sub>, or a cyclic group  
15 selected from C<sub>3-6</sub> cycloalkyl, 3- to 6-membered heterocyclyl, phenyl, monocyclic heteroaryl, and bicyclic heteroaryl, each cyclic group substituted with zero to 3 substituents independently selected from F, Cl, Br, -OH, -CN, C<sub>1-4</sub> alkyl, C<sub>1-2</sub> fluoroalkyl, C<sub>1-3</sub> alkoxy, C<sub>1-2</sub> fluoroalkoxy, and -NR<sub>c</sub>R<sub>c</sub>;

R<sub>4c</sub> is C<sub>1-4</sub> alkyl or C<sub>3-6</sub> cycloalkyl, each substituted with zero to 4 substituents  
20 independently selected from F, Cl, -OH, C<sub>1-2</sub> alkoxy, C<sub>1-2</sub> fluoroalkoxy, and -CN; each R<sub>5</sub> is independently F, -CN, -OH, C<sub>1-5</sub> alkyl substituted with zero to 4 R<sub>g</sub>, C<sub>1-2</sub> alkoxy substituted with zero to 3 R<sub>g</sub>, C<sub>2-3</sub> alkenyl substituted with zero to 4 R<sub>g</sub>, C<sub>2-3</sub> alkynyl substituted with zero to 4 R<sub>g</sub>, C<sub>3-4</sub> cycloalkyl substituted with zero to 4 R<sub>g</sub>, phenyl substituted with zero to 3 R<sub>g</sub>, oxadiazolyl substituted with zero to 3 R<sub>g</sub>,  
25 pyridinyl substituted with zero to 3 R<sub>g</sub>, -(CH<sub>2</sub>)<sub>1-2</sub>(heterocyclyl substituted with zero to 4 R<sub>g</sub>), -(CH<sub>2</sub>)<sub>1-2</sub>NR<sub>c</sub>C(O)(C<sub>1-4</sub> alkyl), -(CH<sub>2</sub>)<sub>1-2</sub>NR<sub>c</sub>C(O)O(C<sub>1-4</sub> alkyl), -(CH<sub>2</sub>)<sub>1-2</sub>NR<sub>c</sub>S(O)<sub>2</sub>(C<sub>1-4</sub> alkyl), -C(O)(C<sub>1-4</sub> alkyl), -C(O)OH, -C(O)O(C<sub>1-4</sub> alkyl), -C(O)O(C<sub>3-4</sub> cycloalkyl), -C(O)NR<sub>a</sub>R<sub>a</sub>, or -C(O)NR<sub>a</sub>(C<sub>3-4</sub> cycloalkyl), or two R<sub>5</sub> attached to the same carbon atom form =O;

30 each R<sub>6</sub> is H, F, or -CH<sub>3</sub>; and

m is zero, 1, 2, or 3.

3. The compound according to claim 1 or a salt thereof, wherein:

R<sub>1</sub> is H, F, -CN, or -OCH<sub>3</sub>;

5 R<sub>2</sub> is H, -CH<sub>3</sub>, -CH<sub>2</sub>CN, -CH<sub>2</sub>CH<sub>2</sub>F, or -CH<sub>2</sub>CH=CH<sub>2</sub>;


R<sub>4</sub> is -CH<sub>2</sub>R<sub>4a</sub> or -CHR<sub>4a</sub>R<sub>4b</sub>;

R<sub>4a</sub> is phenyl, naphthalenyl, or indolyl, each substituted with zero to 2 substituents independently selected from F, -CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>3</sub>, and -OCH<sub>3</sub>;

R<sub>4b</sub> is phenyl or fluorophenyl;


10 each R<sub>5</sub> is -CH<sub>3</sub>, or two R<sub>5</sub> attached to the same carbon atom form =O; and  
m is zero, 1, or 2.


4. The compound according to claim 1 or a salt thereof, having the structure:



15 wherein R<sub>5a</sub> and R<sub>5c</sub> are independently selected from R<sub>5</sub>.

5. The compound according to claim 1 or a salt thereof, having the structure:






6. The compound according to claim 1 or a salt thereof, wherein  $R_4$  is  $-\text{CH}_2\text{R}_{4a}$  or  
 5  $-\text{CH}_2\text{CH}_2\text{R}_{4a}$ .
7. The compound according to claim 1 or a salt thereof, wherein  $R_4$  is  $-\text{CH}_2\text{R}_{4a}$ .
8. The compound according to claim 1 or a salt thereof, wherein  $R_4$  is  $-\text{CHR}_{4a}\text{R}_{4b}$  or  
 10  $-\text{CR}_{4a}\text{R}_{4b}\text{R}_{4c}$ .
9. The compound according to claim 1 or a salt thereof, wherein  $R_4$  is  $-\text{CHR}_{4a}\text{R}_{4b}$ .
10. The compound according to claim 1 or a salt thereof, wherein  $R_4$  is  $-\text{CH}_2\text{R}_{4a}$  or  
 15  $-\text{CHR}_{4a}\text{R}_{4b}$ .
11. A pharmaceutical composition comprising a compound according to claim 1 or a  
 pharmaceutically-acceptable salt thereof; and a pharmaceutically acceptable carrier.
- 20 12. Use of a compound according to any one of claims 1-10 or a pharmaceutically-  
 acceptable salt thereof, for the treatment of cancer or viral infections.

13. The use of claim 12, wherein said cancer is selected from cancer of the colon, pancreatic cancer, breast cancer, prostate cancer, lung cancer, ovarian cancer, cervical cancer, renal cancer, cancer of the head and neck, lymphoma, leukemia and melanoma.

5

14. Use of a compound according to any one of claims 1-10 or a pharmaceutically-acceptable salt thereof, for inhibiting activity of at least one of diacylglycerol kinase selected from diacylglycerol kinase alpha ( $\text{DGK}\alpha$ ) and diacylglycerol kinase zeta ( $\text{DGK}\zeta$ ).

10



(I)